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ABSTRACT 
 
APPLICATION OF SPECIATED ISOTOPE DILUTION MASS SPECTROMETRY TO  
THE ASSESSMENT OF HUMAN HEALTH AND TOXIC EXPOSURE 
 
 
 
By 
Timothy M. Fahrenholz 
December 2011 
 
Dissertation supervised by Professor H. M. “Skip” Kingston 
  
 Previous work by our research group demonstrated that quantitative chemical 
analysis of analytes, such as mercury and chromium species, in environmental matrices 
could be successfully carried out without using calibration curves and with correction for 
species interconversion by using EPA Method 6800A. This method encompasses isotope 
dilution mass spectrometry (IDMS) and speciated isotope dilution mass spectrometry 
(SIDMS), both of which are described in detail in chapter 1. Research described in this 
dissertation expands upon our earlier work by applying the method to the speciation of 
mercury in biological matrices, the speciation of glutathione in red blood cells and whole 
blood, and the analysis of enzyme activity in mammalian tissue.  
  v 
For example, in an experiment involving mercury speciation in a hair sample 
(chapter 2), EPA Method 6800A corrected for the conversion of over 70% of the 
C2H5Hg
+
 to Hg
2+
, as well as other conversions that occurred, so that the correct 
concentrations of all mercury species present could be obtained.  
  EPA Method 6800A was also used for the analysis of glutathione in red blood 
cells in two autism studies (chapter 3). In one of the studies, analysis of 16 matched pairs 
of control and autistic samples demonstrated that red blood cell total glutathione 
concentrations were higher in samples from autistic patients than ones from controls 
(p=0.012), suggesting that the autistic patients studied may be making more glutathione 
in response to a larger toxic burden of heavy metals such as lead, antimony, aluminum, 
and cadmium, compared to controls. 
 Another application of EPA Method 6800A involved the analysis of alpha – 
Galactosidase A (GLA) activity in liver, kidney, and brain tissues harvested from mice as 
part of the development of a gene therapy animal model for Fabry’s disease (chapter 4). 
In this study, EPA Method 6800A successfully distinguished between samples from gene 
deficient and wild type mice, as well as mice exposed to two different dosages for gene 
therapy treatment.  
 The successful application of EPA Method 6800A in biological matrices 
described in this dissertation should serve to foster further usage of it in fields such as 
medicine, toxicology, and agriculture.     
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Introduction: Human Environmental Health and The Importance of Mercury and 
Glutathione Speciation: the toxicant and immune system 
 
Environmental health is a relatively new field, and yet it has been known 
anecdotally for decades and is a result of our industrial revolution that has forever altered 
our environment.  There is great concern about how toxicants which are being introduced 
into the environment are impacting lifespans and the quality of people’s lives. Of the over 
80,000 chemicals registered with the U.S. Environmental Protection Agency, only about 
200 have undergone extensive testing for neurotoxicity (1).  It has been suggested by the 
National Academy of Sciences that 3% of developmental disorders may be attributed to 
exposure to environmental toxicants and that another 25% could result from a 
combination of environmental and genetic factors (2). As the environment evolves, it is 
necessary to respond to these new toxicological insults; however, new metrologies are 
only now being developed to keep pace with this evolution of environment and health 
related repercussions.   
This dissertation is a study of both the toxicants and the immune system 
components.  It is both the development of metrology and its application to children’s 
neurological health.  We will begin in this introductory chapter by discussing a specific 
area of environmental concern (mercury) and progress to the immune system and the 
human response. In subsequent chapters, research pertaining to the metrology enabling 
the assessment of both will also be discussed. 
 
 
  xi 
I. The Toxicant and Species of Mercury 
 Mercury is a ubiquitous element in the environment which has been 
known for centuries. It was called “quicksilver” by Aristotle (3), and historical evidence 
suggests that it was used for gold extraction as far back as about 290 A.D. (4). The 
uptake, distribution, and excretion pathway of mercury in the body depends on its species 
(3). Elemental mercury (Hg
O
), which can enter the atmosphere from the activity of 
volcanoes and from coal fired power plants (5), can come into the body through 
inhalation and penetrate the blood-brain barrier, with the main non-occupational exposure 
of it coming from dental amalgams (5). Inorganic mercury (Hg
2+
) primarily targets the 
kidney, from which it can be eliminated through the urine (5). Sources of Hg
2+ 
include 
cosmetic creams and batteries (5). Methylmercury (CH3Hg
+
) is a neurotoxin (6), and the 
main source of human exposure to it comes from the consumption of fish (7). Tables 1 - 3 
are taken from the FDA website and show the mercury levels in various types of fish (8). 
It should be noted that the legal limit for mercury in commercial fish in the United States 
is 1 ppm (9). For pregnant mothers, nursing mothers, women of childbearing age, and 
small children, the FDA recommends avoiding fish that is high in mercury, such as 
swordfish, and limiting intake of low mercury fish, such as salmon, to 12 ounces per 
week (10). 
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 Another form of mercury, ethylmercury (C2H5Hg
+
), is a metabolic product of 
Thimerosal, a preservative that was commonly used in childhood vaccines and is still 
used in the influenza vaccine (11). The structure of Thimerosal is shown in Figure 1: 
 
    Figure 1 – Thimerosal structure 
  xv 
There has been much controversy over the years regarding the possible link between 
autism and the usage of Thimerosal in vaccines. Recent large scale studies seem to 
suggest the absence of such a link, although some have speculated that certain autistic 
children may have greater genetic susceptibility to mercury toxicity, which could in turn 
activate latent autism upon exposure (12).   
 So far in this introduction, several species of mercury have been described. One 
of the biomolecules involved in the body’s defense against mercury species and other 
toxicants is glutathione. This important biomolecule is described in the next section. 
 
II.  Species of Glutathione 
Glutathione (GSH) is a tripeptide consisting of glutamate, cysteine, and glycine 
and is synthesized in every cell the body (13). The structure of GSH is shown in Figure 2: 
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Figure 2 – GSH 
 
It is involved in several important functions, such as antioxidant activity and xenobiotic 
detoxification (14). The key functional role is played by the cysteine thiol group, which is 
involved in conjugation and reduction reactions (15).  Cysteine (the rate limiting amino 
  xvi 
acid for GSH synthesis), can be synthesized by the body through a series of steps from 
methionine, but according to Dr. S. Jill James, et al., this pathway appears to function 
poorly in autistic children, thereby effectively rendering cysteine an essential amino acid 
for them (16). The James research group has also analyzed GSH, glutathione disulfide 
(GSSG –  disulfide dimer formed from two GSH molecules, shown in Figure 3), and total 
GSH (tGSH)  in plasma samples from autistic children and healthy controls and found 
that autistic children have lower plasma tGSH levels as well as lower plasma GSH/GSSG 
ratios (often used as an indication of oxidative stress level) compared to the healthy 
controls (13).  
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Figure 3 – GSSG 
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Strategies that are used to boost GSH levels include the consumption of protein 
foods with cysteine (17) and the intake of supplements which function as cysteine 
precursors, such as N-acetylcysteine (NAC), the structure of which is shown in Figure 4 
(18).   
N
O
OHH
SH
H
O
 
    Figure 4 – N-acetylcysteine (NAC) 
 
III. Mercury – GSH Conjugates 
 As mentioned earlier, glutathione plays an important role in the detoxification of 
xenobiotics.  For example, Hg
2+
 can bind to two GSH molecules as indicated in Figure 5, 
at which point it is either eliminated in the urine in that form or further metabolized and 
then eliminated in the urine (21).   
HO N
H
H
N
OH
O O
O
O
NH2
S
S
N
H
H
N
O
NH2
OH
O
O
HO
O
Hg
 
Figure 5 – Hg2+ conjugated with two GSH molecules  
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With respect to CH3Hg
+
, evidence suggests that an important step in its detoxification is 
the secretion of a CH3Hg
+
 - GSH conjugate, shown in Figure 6, from liver cells into bile 
(20). 
HO
N
H
H
N OH
OOO
S
Hg
O NH2
CH3  
    Figure 6 – CH3Hg
+
 conjugated with GSH 
 
 
In the body, the CH3Hg
+
 - GSH conjugate can be converted to a CH3Hg
+
  - cysteine 
conjugate, which structurally resembles the amino acid methionine (20), and evidence 
suggests that it is this resemblance which enables the CH3Hg
+
 - cysteine conjugate to 
penetrate the blood-brain barrier (21). As shown in Figure 7 below, in a pregnant woman, 
some of the CH3Hg
+
 taken in through the diet can get converted to Hg
2+
 and eliminated in 
the feces, some can enter the brain, some can be eliminated through hair, and some make 
it past the placenta into the unborn child (20). It can also enter the kidney, liver, cardiac 
muscle, and skeletal muscle as well (21), and in blood, most of the CH3Hg
+
  is 
concentrated in the red blood cells, rather than the plasma (20). 
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Figure 7 – Fates of CH3Hg
+
 in a woman who is pregnant (21) 
 
A study by Adams et al. in which GSH in red blood cells and heavy metals in urine from 
autistic children were analyzed before and after chelation therapy suggested that exposure 
to toxic metals other than mercury, such as lead, aluminum, cadmium, and antimony 
results in higher than normal GSH levels due to the body’s increased GSH synthesis in 
response to exposure to those metals, while exposure to mercury results in lower than 
normal GSH levels, possibly due to the inhibition of GSH synthesis by the mercury (22). 
The study also suggested that, as the body burden of toxic metals is lowered, the 
concentration of GSH in red blood cells normalizes (22). Additionally, a separate study 
by James et al. showed that depleted levels of GSH in neuroblastoma and glioblastoma 
cells resulted from the exposure of those cells to Thimerosal (23), the preservative with 
the C2H5Hg
+
 group mentioned the first part of this introduction which some have 
suggested might play a role in the onset of autism in a vulnerable genetic subset of the 
population.  
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IV. Metallothionein and GSH 
Studies also show that there is a synergistic relationship between GSH and 
Metallothionein (MT), a cysteine rich protein which stores zinc and is also involved in 
heavy metal detoxification. Specifically, GSH inhibits the release of zinc from MT while 
GSSG activates it, and the greater the level of oxidative stress, the greater the amount of 
zinc that is released from MT in response, which may be due to the need for zinc as part 
of an antioxidant defense mechanism (24). This relationship is illustrated in Figure 8, 
which was modified from Kang, Y. (24) by Hemasudha Chatragadda, a graduate student 
in the Kingston Research group at Duquesne University, in collaboration with Dr. Martha 
Herbert from Harvard University. 
 
Figure 8 – Relationship between MT and GSH, modified from Kank, et al.  (24) 
by Hemasudha Chatragadda, a graduate student in the Kingston Research group at 
Duquesne University 
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V. Goals of the Research Projects Described in this Dissertation 
 
According to the Center for Disease Control, on average, 1 in 110 children in the 
United States has an autism spectrum disorder (ASD) (25). The prevalence is even higher 
in other countries, such as South Korea, where about 1 in 38 children has an ASD (26). 
With the high prevalence of autism in several locations, a significant amount of research 
is being conducted to try to determine what is causing such a high prevalence, as well as 
how to detect autism early in life, as evidence suggests that early intervention can have a 
positive impact on these autistic children (27). The discovery and use of autism 
biomarkers may enable medical professionals to make an early diagnosis of autism so 
that they can implement early intervention strategies. One of the goals of the research 
described in this dissertation is to follow up on the work of Dr. S. Jill James and others 
with respect to the potential use of GSH as a biomarker for autism.  
Another goal of the research described in this dissertation is to improve upon 
already existing technology for the speciation of mercury in biological matrices such as 
hair and blood. This can help with clinical evaluation of one’s level of mercury toxicity, 
as some forms of mercury are more toxic than others.  
An additional goal of the research described in this dissertation is to improve 
upon existing technology for the evaluation of enzyme activity. The successful 
achievement of this goal can also have applications in the diagnosis and treatment of 
diseases.  
  xxii 
 The research undertaken to achieve all of these goals involved the implementation 
of advanced methodology using special sample preparation techniques along with mass 
spectrometry. This advanced methodology is described chapter 1.  
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Chapter 1 
 
Metrology: Overview of Isotope Dilution Mass Spectrometry (IDMS) and  
Speciated Isotope Dilution Mass Spectrometry (SIDMS) 
 
  Metrology is the study of measurement.  The International Union of Pure 
and Applied Chemistry (IUPAC) recognizes only four fundamental measurement types 
that are definitive.  Definitive by definition means that all the biases and errors can be 
accessed, measured and known and corrected for to achieve a reliable and bias free 
measurement possessing known accuracy and precision. Over the past 60 years the 
science and art of Isotope Dilution Mass Spectrometry (IDMS), has evolved and 
developed.  IDMS, which involves spiking a given sample with a known concentration 
and amount of a stable isotopically enriched form of the analyte of interest, equilibrating 
the elemental or molecular forms so that both spike and natural are in exactly the same 
species form, then performing a mass spectrometry measurement on the equilibrated  
sample, and determining the concentration of the analyte based upon peak ratios, was 
originally developed during the 1950s for elemental analysis (1). Frequently in IDMS, the 
analyte species are converted to one form so that there is only one species for both the 
natural and the spike analyte.  Over the years, the usage of enriched isotopes for 
quantitative mass spectrometry analysis has been applied to fields such as environmental 
chemistry (2), clinical chemistry, pharmacokinetics, and toxicology (3). An equation for  
IDMS is shown in Figure 1 solved for the concentration of the analyte (4): 
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Figure 1 – IDMS equation 
Where: 
 Ax = abundance of isotope A in the natural abundant analyte in the sample 
 Bx = abundance of isotope B in the natural abundant analyte in the sample 
 As = abundance of isotope A in the enriched analyte in the spike 
 Bs = abundance of isotope B in the enriched analyte in the spike 
 Cx = concentration of the natural abundant analyte in the sample, which is what 
the equation is solving for 
 Cs = concentration of enriched analyte in the spike in µmol/g 
 Wx =  weight of the sample 
 Ws =  weight of the spike 
 Rm = measured ratio of isotope A to isotope B (obtained from the mass 
spectrometry measurements)  
 
An example of an IDMS calculation with tGSH is shown next: 
 
 
  3 
Application of IDMS to GSH 
 When GSH is analyzed by tandem electrospray mass spectrometry (ESI-MS-MS),  
the collision energy can be adjusted such that the cysteinylglycine product ion (resulting 
from the loss of pyroglutamate – 129 g/mol) is obtained and is the most abundant product 
ion (5), as shown below in Figure 2:  
 
Figure 2 – Fragmentation of GSH in the collision cell resulting in the formation of the 
cysteinylglycine product ion of interest (in the green box)  
 
Natural abundant GSH (307 g/mol): 
- Most abundant isotope detected at 308 m/z in positive mode ESI-MS 
- Main product ion (depending on collision energy) detected at 179 m/z in 
MS/MS mode (loss of pyroglutamate) 
Enriched GSH -  has two 
13C’s and one 15N on the glycine (310 g/mol) 
- Most abundant isotope detected at 311 m/z in positive mode ESI-MS 
- Main product ion (depending on collision energy) detected at 182 m/z in 
MS/MS mode (loss of pyroglutamate)  
 
  4 
IDMS calculation of tGSH concentration: 
 
- Ax = abundance of 182 m/z product ion in the natural abundant analyte in the 
sample (0.00341) 
- Bx = abundance of 179 m/z product ion in the natural abundant analyte in the 
sample (0.881) 
- As = abundance of 182 m/z product ion in the enriched analyte in the spike 
(0.881) 
- Bs = abundance of 179 product ion in the enriched analyte in the spike 
(0.00224) 
- Cx = concentration of GSH in the sample (unknown) 
- Cs = concentration of enriched GSH in the spike in µmol/g (2.09) 
- Wx =  weight of the sample (0.247 g) 
- Ws =  weight of the spike (0.251 g) 
- Rm = measured ratio of 182 m/z product ion to 179 product ion (obtained from 
the mass spectrometry measurements)  (1.21) 
- Cx = [((2.09 µmol/g)(0.251g))/(0.247g)] x [((0.881) – (1.21 x 0.00224))/((1.21 
x 0.881) – 0.00341)] = 1.76 µmol/g 
- Molecular weight of GSH = 307 µg/µmol 
- Cx in µg/g (or ppm) = (1.76 µmol/g)(307 µg/µmol) = 540 ppm 
 
Speciated Isotope Dilution Mass Spectrometry (SIDMS) entails spiking a sample 
with known amounts of stable isotopically enriched analyte species, achieving 
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equilibration of spike and analyte species, performing mass spectrometry on the 
equilibrated sample, and determining concentrations based upon ratios and the extent of 
interconversion between or among species (4). This method, which was patented by H.M. 
Skip Kingston, represented an advancement beyond traditional IDMS by correcting for 
species interconversions that occurred during sample preparation and/or measurement 
(6).  These two methods (IDMS and SIDMS) constitute EPA Method 6800A (4). 
Examples of SIDMS equations will be presented later in this section. 
 EPA Method 6800 A does not use traditional calibration curves and has several 
advantages over the more traditional calibration curve method of analysis. Among them 
include the absence of several sources of error common to the calibration curve method, 
as illustrated in Figure 3 below: 
Sources of Errors in Mass Spectrometric Analysis
• Stability of analyte in solution
• Accuracy in sample preparation
• Purity of calibration standards
• Choice of internal standard
• Improper instrumental setup
• Total dissolved solids
• Non-spectral interferences  
• Matrix matching
• Standard addition
• Sample introduction
• Calibration curve inaccuracies
• Chromatographic separation
• Instrument drift with time
• Nebulization efficiency
• Droplet size
• Physical properties of solution
• Acid content in the solution
• Analyst’s lack of knowledge/training
• Background correction
Calibration Curve
(not a definitive method)
• More instrument time
• More analyst time
• More reagents and chemicals
• More overall expense
Isotope Dilution and
Speciated Isotope Dilution
(definitive method)
• Direct mathematical solution 
based on traditional and new 
mathematical algorithms
• Mass bias 
• Dead time
• Interferences-Isobaric & polyatomic
• Signal suppression of the isotope in 
excess over the one that is limited 
 
Figure 3 Comparing error sources from calibration curve analysis vs EPA Method 6800A 
 
As can be seen in Figure 3, the number of error sources from the usage of EPA 6800A is 
significantly less than that from the usage of calibration curves. Only mass bias, dead 
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time correction, isobaric interferences, and possible signal suppression of the excess 
isotope over the limited isotope remain for the former method.  
 EPA Method 6800A also represents an improvement over the more common 
internal standard method, which involves spiking the sample with a known amount of an 
element or a molecular compound (depending on the application), performing mass 
spectrometry on the sufficiently prepared sample (in its mass spectrometry application), 
and calculating the concentration of the analyte based upon the intensity of the analyte 
signal relative to the intensity of the internal standard signal (similar to, but not exactly 
the same as, the method which utilizes the equation in figure 1).  Both methods have the 
advantage over the calibration curve method of enabling the analyst to correct for 
fluctuations in signal intensity and for reductions in sample recovery; however, if one is 
attempting to measure two or more species of an element or a molecular compound, and 
there are interconversions between or among the species of interest, SIDMS can correct 
for these interconversions.  
 SIDMS is particularly suited for the measurement of two species in which one can 
convert to the other, such as the related species pair of GSH and GSSG. One of the more 
common analyses that has given researchers difficulty with respect to conversion of one 
species to another over the years has been that of GSH and GSSG, a particularly 
important analysis from which one can obtain the GSH/GSSG ratio. As mentioned in the 
introduction, this ratio is often used as an indicator of oxidative stress and has been 
shown to be lower in plasma samples from autistic children than in ones from healthy 
controls (7).  
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To elaborate on the challenges with GSH and GSSG analysis, a potential 
difficulty that researchers have had has been the conversion of the former to the latter 
during sample preparation (8). A reagent often used to prevent this conversion is N-
Ethylmaleimide (abbreviated NEM) (9), which blocks the thiol group on the GSH as 
shown below in Figure 4: 
 
Figure 4 – GSH NEM reaction 
 
An additional characteristic of NEM is that it inhibits Glutathione reductase (GR), an 
enzyme which converts GSSG back to GSH (8).  SIDMS can complement the usage of 
NEM by correcting for imperfections in its usage, such as the possible conversion of 
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GSH to GSSG before the NEM had a chance to react fully and the reduction in recovery 
of GSSG, which can result from the reaction of NEM with its amines (7).   
 In describing the SIDMS equations for GSH and GSSG analysis that are designed 
to correct for conversion of GSH to GSSG, it is best to start off with a simple analogy. If 
one has several slices of wheat bread and several slices of white bread, one can make 
three types of sandwiches: ones with two slices of wheat bread, ones each with a slice of 
wheat bread and a slice of white bread (“hybrid” sandwiches), and ones with two slices of 
white bread. In a similar manner, if natural abundant GSH (307 g/mol) and isotopically 
enriched GSH with two 
13C’s and one 15N (310 g/mol) are equilibrated and oxidation 
occurs, one can end up with three types of oxidized GSSG: natural abundant GSSG (612 
g/mol) from two molecules of natural abundant GSH (analogous to wheat bread 
sandwiches), partially enriched GSSG (615 g/mol) with two 
13C’s and one 15N from the 
combination of one natural abundant GSH molecule and one isotopically enriched GSH 
molecule (analogous to the “hybrid” sandwiches), and GSSG with four 13C’s and two 
15N’s (618 g/mol) from two molecules of enriched GSH (analogous to the white bread 
sandwiches).  One can determine how much of the GSH converted to GSSG by spiking 
the sample with enriched GSSG in which the enrichment is different from the enriched 
GSSG that comes from oxidation (such as GSSG that has four 
13C’s (616 g/mol). 
 Suppose one has 1 mole of wheat bread slices (6.02 x 10
23
 slices), referred to as 
“n” and the same number of white bread slices, referred to as “m,” that gets converted to 
sandwiches. Mathematical relationships pertaining to the number of each kind of 
sandwich formed, which were worked out by Dr. John Kern from the Mathematics 
department at Duquesne University (10), are described on the following pages. 
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φ =  # of ways to select k items from w = w!/[k! (w-k)!] 
e.g. if w=9 and k=2,  
φ = (9 x 8 x 7 x 6 x 5 x 4 x 3 x 2 x 1)/(2!)(7 x 6 x 5 x 4 x 3 x 2 x 1) = (9 x 8)/2 = 36 
If w is an extremely large number (such as 6.02 x 10
23
) and k = 2, for all practical 
purposes, φ = w2/2 
The total number of sandwich combinations = [(n + m)!]/ k! ((n + m)-k)!]  
                   = [(6.02 x 10
23
 + 6.02 x 10
23
 )(6.02 x 10
23
 + 6.02 x 10
23
 – 1)]/2 
 = [(12.04 x 10
23
)(12.04 x 10
23
 – 1)]/2 
(neglect -1) = (12.04 x 10
23
)
2
/2 = 7.25 x 10
47 
sandwiches  
  = (n + m)
2
/2 
The probability (expressed as a decimal) of getting a wheat bread sandwich 
 = [(n
2
)/2]/[(n + m)
2
/2] 
 = [(6.02 x 10
23
)
2
/2]/[(12.04 x 10
23
)
2
/2] 
 = (6.02 x 10
23
)
2
/ (12.04 x 10
23
)
2
 = 0.250 
The probability (expressed as a decimal) of getting a white bread sandwich  
= [(m
2
)/2]/[(n + m)
2
/2] 
= [(6.02 x 10
23
)
2
/2]/[(12.04 x 10
23
)
2
/2] 
= (6.02 x 10
23
)
2
/ (12.04 x 10
23
)
2
 = 0.250 
The probability (expressed as a decimal) of getting a sandwich with one slice of wheat 
bread and one slice of white bread = (n x m)/[(n + m)
2
/2] 
= 2mn/(n + m)
2
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= [(2)(6.02x10
23
)(6.02x10
23
)]/ (6.02x10
23
 + 6.02x10
23
)
2
  
= 0.500 
The same 0.500 answer can be obtained by using units of moles instead 
= [(2)(1mole)(1mole)]/(1mole+1mole)
2
  
= 0.500 
 These mathematical relationships can be applied to GSH and GSSG analysis.  Let 
“n” = the µmol of natural abundant 307 g/mol GSH that became oxidized either to natural 
abundant 612 g/mol GSSG or “hybrid” 615 g/mol GSSG. Let “m” = the µmol of 
isotopically enriched 310 g/mol GSH that became oxidized to either “hybrid” 615 g/mol 
GSSG or fully enriched 618 g/mol GSSG. The ratio of the probability of getting “hybrid” 
615 g/mol GSSG (sandwich with one slice of wheat bread and one slice of white bread) 
to the probability of getting fully enriched 618 g/mol GSSG (sandwich with two slices of 
white bread) equals the ratio of the peak areas from LC/MS/MS analysis of the peaks in 
the chromatogram representing those species of GSSG (after taking into account the 
abundances of those isotopes and subtracting out the contribution coming from natural 
abundant GSSG).  
In positive mode ESI-MS, the most abundant isotope from natural abundant 612 
g/mol GSSG is detected at 613 m/z, that from “hybrid” 615 g/mol GSSG with two 13C’s 
and one 
15
N is detected at 616 m/z, that from enriched 616 g/mol GSSG with four 
13C’s is 
detected at 617 m/z, and that from enriched 618 g/mol GSSG with four 
13C’s and two 
15N’s (which came from two 310 g/mol GSH’s that each had two 13C’s and one 15N) is 
detected at 619 m/z. In positive mode electrospray tandem mass spectrometry (ESI-
MS/MS) with the collision energy adjusted so as to make the most abundant product ion 
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that which results from the loss of two pyroglutamates from GSSG (loss of 258 g/mol), 
the numbers above change to 355 m/z, 358 m/z, 359 m/z, and 361 m/z, respectively. The 
mathematical relationship described on the next two pages can be used to determine GSH 
and GSSG concentrations. 
 
(358 m/z peak area)/(361 m/z peak area) 
= (probability of getting “hybrid” 615 g/mol GSSG)/(that of getting  618 g/mol GSSG) 
= [(2mn)/(n+m)
2
]/[(m
2
)/(m+n)
2
] 
= 2n/m 
m = µmol of 310 g/mol GSH that became oxidized 
     = (2 x µmol of 618 g/mol GSSG present) + (µmol of 615 g/mol GSSG present) 
 
The mass of the solution of the enriched 310 g/mol GSH that was added is known, 
as is the mass and concentration of the enriched 616 g/mol GSSG solution. One can 
determine the concentration (and, thus, µmol) of the 618 g/mol GSSG and 615 g/mol 
GSSG present by performing IDMS on both with the 616 g/mol GSSG representing the 
enriched analyte.  One µmol of 618 g/mol GSSG comes from two µmols of 310 g/mol 
GSH, and one µmol of 615 g/mol GSSG comes from one µmol each of 307 g/mol GSH 
and 310 g/mol GSH.  Using this relationship, one can determine “m” (the µmol of 310 
g/mol GSH that became oxidized).  Once “m” is known, one can determine “n” (the µmol 
of natural abundant 307 g/mol GSH that converted to either 612 g/mol GSSG or 615 
g/mol GSSG) using the following relationship 
[(358 m/z peak area)/((361 m/z peak area)*(2))]*m  
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= n  
= µmol of 307 g/mol GSH that became oxidized 
 Since the mass of the sample (e.g. blood sample, plasma sample, etc.) is known, one can 
determine the concentration of GSH that became oxidized to GSSG in units of µmol /g 
(and, subsequently, µg/g)  and perform the necessary subtraction from the uncorrected 
GSSG concentration and the necessary addition to the uncorrected GSH concentration.  
Another area in which SIDMS can be applied is mercury speciation. As 
mentioned in the introduction, different species of mercury have different levels of 
toxicity and different target organs, hence the need for the analysis of the individual 
mercury species, rather than just total mercury, in order to determine one’s level of toxic 
exposure.  Dr. G.M. Mizanur Rahman from Duquesne University described in his 
doctoral dissertation from 2004 the SIDMS equations that can be used for Hg
2+
 and 
CH3Hg
+
 speciation, which are shown below and on the next pages (11): 
For Hg
+
 
        
    
= [(
199
Ax  
    
Wx + 
199  
    
  
    
  
    
) (1 – α) + 
 (
199
Ax  
CH 3 Hg+Wx + 
199  
CH 3 Hg+  
CH 3 Hg+  
CH 3 Hg+)β]/ 
 [(
202
Ax  
    
Wx + 
202  
    
  
    
  
    
) (1 – α) + 
  (
202
Ax  
CH 3 Hg+Wx + 
202  
CH 3 Hg+  
CH 3 Hg+  
CH 3 Hg+)β] 
        
    
= [(
201
Ax  
    
Wx + 
201  
    
  
    
  
    
) (1 – α) + 
 (
201
Ax  
CH 3 Hg+Wx + 
201  
CH 3 Hg+  
CH 3 Hg+  
CH 3 Hg+)β]/ 
 [(
202
Ax  
    
Wx + 
202  
    
  
    
  
    
) (1 – α) + 
  (
202
Ax  
CH 3 Hg+Wx + 
202  
CH 3 Hg+  
CH 3 Hg+  
CH 3 Hg+)β] 
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For CH3Hg
+
 
           = [(
199
Ax  
    
Wx + 
199  
    
  
    
  
    
)α + 
 (
199
Ax  
CH 3 Hg+Wx + 
199  
CH 3 Hg+  
CH 3 Hg+  
CH 3 Hg+) (1 – β)]/ 
 [(
202
Ax  
    
Wx + 
202  
    
  
    
  
    
)α + 
  (
202
Ax  
CH 3 Hg+Wx + 
202  
CH 3 Hg+  
CH 3 Hg+  
CH 3 Hg+) (1 – β)] 
           = [(
201
Ax  
    
Wx + 
201  
    
  
    
  
    
)α + 
 (
201
Ax  
CH 3 Hg+Wx + 
201  
CH 3 Hg+  
CH 3 Hg+  
CH 3 Hg+) (1 – β)]/ 
 [(
202
Ax  
    
Wx + 
202  
    
  
    
  
    
)α + 
  (
202
Ax  
CH 3 Hg+Wx + 
202  
CH 3 Hg+  
CH 3 Hg+  
CH 3 Hg+) (1- β)] 
Where,  
        
    
is the isotope ratio of 
199
Hg to 
202
Hg of Hg
2+
 in the spiked sample (unknown) 
        
    
is the isotope ratio of 
201
Hg to 
202
Hg of Hg
2+
 in the spiked sample (unknown) 
          is the isotope ratio of 
199
Hg to 
202
Hg of CH3Hg
+
 in the spiked sample 
(unknown) 
          is the isotope ratio of 
201
Hg to 
202
Hg of CH3Hg
+
 in the spiked sample 
(unknown)  
199
Ax is the relative isotope abundance of 
199
Hg in the sample 
202
Ax is the relative isotope abundance of 
202
Hg in the sample 
201
Ax is the relative isotope abundance of 
201
Hg in the sample 
199  
     
is the relative isotope abundance of 
199
Hg in the 
199
Hg
2+
 spike 
202  
     
is the relative isotope abundance of 
202
Hg in the 
199
Hg
2+
 spike 
201  
     
is the relative isotope abundance of 
201
Hg in the 
199
Hg
2+
 spike 
CH3Hg
+ 
CH3Hg
+ 
CH3Hg
+ 
CH3Hg
+ 
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199  
CH 3 Hg+ is the relative isotope abundance of 
199
Hg in the CH3
201
Hg
+
 spike 
202  
CH 3 Hg+ is the relative isotope abundance of 
202
Hg in the CH3
201
Hg
+
 spike 
201  
CH 3 Hg+ is the relative isotope abundance of 
201
Hg in the CH3
201
Hg
+
 spike 
  
    
 is the concentration of Hg
2+
 in the sample (µmol/g, unknown) 
  
CH 3 Hg+ is the concentration of CH3Hg
+
 in the sample (µmol/g, unknown) 
Wx is the weight of the sample (g) 
  
     
is the concentration of Hg
2+
 in the 
199
Hg
2+
 spike (µmol/g) 
  
     
is the weight of the 
199
Hg
2+
 spike (g) 
  
CH 3 Hg+ is the concentration of CH3Hg
+
 in the CH3 
201
Hg
+
 spike (µmol/g) 
  
CH 3 Hg+ is the weight of the CH3 
201
Hg
+
 spike (g) 
α is the proportion of Hg2+ transformed to CH3Hg
+
 (unknown) 
β is the proportion of CH3Hg
+
 transformed to Hg
2+
 (unknown) 
 
In more recent years, our laboratory has used CH3
200
Hg
+
 in place of CH3
201
Hg
+
, in part 
because the 
201
Hg isotope is now used for enriched C2H5Hg
+
 (C2H5 
201
Hg
+
) so as to 
enable one to perform SIDMS with three Hg species (Hg
2+
, CH3Hg
+
, and C2H5Hg
+
 ) 
using SIDMS equations for three-species analysis that were also described in Dr. 
Rahman’s dissertation (11). It was considered important to add C2H5Hg
+
 to the number of 
mercury species analyzed is because, as mentioned in the introduction, it is a metabolic 
product of Thimerosal, a preservative still used in some vaccines, such as the influenza 
vaccine (12).   
 In summation, the speciation of glutathione and mercury is of critical 
toxicological importance and can be achieved without calibration curves by using EPA 
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Method 6800A.  The following chapters will describe these applications and 
developments for these specific analyses.  
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Chapter 2 – Development and Refinements of Application of IDMS and SIDMS to 
Mercury Speciation in Specific Matrices 
 
2 A. Mercury Speciation in Hair 
 As mentioned in the introduction, one of the fates of CH3Hg
+
 in the body is 
elimination through the hair (1). A normal concentration of hair mercury is between 0.4 
and 6 ppm (2), with most (over 90%) of the mercury consisting of CH3Hg
+
 (3). 
According to the EPA, a toxic threshold for hair mercury is 10 ppm (4). Evidence 
indicates hair mercury concentration increases with increasing fish consumption (5).  
During the sample preparation and analysis of samples with both CH3Hg
+
and 
Hg
2+
, methylation of inorganic mercury and demethylation of CH3Hg
+
 occur.  IDMS is 
capable of analyzing total mercury but it is not capable of correcting for these 
interconversions of the two related species of mercury. For these corrections, SIDMS, in 
its most applicable form as described in EPA method 6800A, must be applied.  In the 
application of 6800A, there are optimizations that can be applied, and these are part of 
the scientific contribution demonstrated in this chapter. 
In addition to CH3Hg
+
and Hg
2+
, C2H5Hg
+
, which is a metabolic product of 
Thimerosal, has also been detected in human hair (6,7), as well as blood (7) from persons 
exposed to Thimerosal. Studies from mice and rats suggest that C2H5Hg
+
from Thimarosal 
can be converted to Hg
2+
 in mammals (8,9),  and a study of infants exposed to 
Thimerosol suggests that mercury from the Thimerosal exposure can be eliminated 
through the stools (10). More research needs to be undertaken to determine the fates of 
C2H5Hg
+
 in the body. 
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 To illustrate the importance of accounting for possible species interconversion, as 
well as the importance of taking into consideration percent recovery of the analytes of 
interest, a set of experiments was completed in our laboratory in which several literature 
hair sample preparation protocols were assessed by traditional external calibration. This 
set of experiments is described in the next section. 
 
2A i. Analysis of Mercury Species in hair using published sample preparation 
protocols with traditional external calibration 
 
Materials and Methods  
Reagents/standards:  
 The hair standard used was a certified reference material (IAEA – 085) from the 
International Atomic Energy Agency (Vienna, Austria) that was certified for total 
mercury and methylmercury. The water used for solutions was double deionized (DDI) 
water from a Barnstead NANOpure Ultrapure Water System (Dubuque, IA).  Reagent 
grade nitric acid, hydrochloric acid, hydrogen peroxide, L-cysteine, and ethanol were 
obtained from Fisher Scientific (Pittsburgh, PA). Both nitric acid and hydrochloric acid 
were purified using sub-boiling distillation in a quartz still (Milestone, Monroe, CT).  
 
Instrumentation/analytical methods: 
 For analysis of the prepared samples, liquid chromatography-inductively coupled 
plasma-MS (LC-ICP-MS) analysis was performed using isocratic elution with a Waters 
(Milford, MA) Novapak C18 reversed phase column (150 x 3.9 mm, 4 µm) and a 709 IC 
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polymeric inert pump with an 838 advanced sample processor for automatic sample 
delivery from Metrohm Peak (Houston, TX) coupled to an Agilent 4500 ICP-MS 
(Agilent Technologies, Palo Alto, CA). The mobile phase consisted of 0.4% cysteine, pH 
5. The flow rate was 1.0 ml/min, and the injection volume was 100 µl. The 
chromatography and automation equipment were situated in a high efficiency particulate 
air (HEPA) filter class 100 clean hood chamber next to the ICP-MS in a class 1000 clean 
room laboratory. For data evaluation using external calibration, quantification was based 
on chromatographic peak area by monitoring the signal for the 
202
Hg isotope. For each 
sample preparation method, four sample preparation replicates and four analysis 
replicates were completed (n=16).  
 
Sample preparation methods used from the literature (note –four sub samples of the 
mercury hair samples were prepared in each case, procedural blanks were prepared 
with the samples for quality assurance purposes): 
 
Method 1 (from reference 11) 
 For acid leaching with 2 M HCl, four 50 mg sub-samples of the hair reference 
material were each placed into a 15-mL disposable glass centrifuge tube with a snap-on 
cap, to which two drops of ethanol and 5 ml of 2 M HCl were added. A small amount of 
mercury-free cotton was added to prevent the hair from floating. Each centrifuge tube 
was tightly capped and heated at 100
o
C in a water bath for 5 minutes. After cooling, the 
sample solutions were then stirred well using a vortex mixer and centrifuged for 5 
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minutes at 3200 rpm to separate the hair. Each cooled extract was transferred to a tarred 
50-mL polypropylene centrifuge tube and diluted to 20 mL by adding DDI water. 
 
Method 2 (from reference 12) 
 For acid leaching with 2 M HCl, four 100 mg portions of hair sample were placed 
into 15 mL disposable glass centrifuge tubes with a snap on caps, to which 2 ml of 2M 
HCl were added. The centrifuge tubes were tightly capped and heated at 100
o
C  in a 
water bath for 15 minutes. The sample solutions were then centrifuged for 5 minutes at 
3200 rpm to separate the hair. The cooled extracts were transferred into tarred 50 ml 
polypropylene graduated centrifuge tubes and diluted to 20 mL by adding DDI water. 
 
Method 3 (from reference 13) 
 For acid leaching with 4% (v/v) HCl, a 3 ml portion of 4% (v/v) HCl was shaken 
on a mechanical shaker with 200 mg of hair for 2 minutes. The hair was then separated 
by centrifugation at 2700 rpm for 20 minutes. The supernatant containing the 
methylmercury was transferred into a tarred 50 mL polypropylene graduated centrifuge 
tube. The process was repeated with 2 ml of 4% (v/v) hydrochloric acid, and the 
combined supernatants were diluted to 20 mL with DDI water. Four sample replicates 
were prepared.  
 
Method 4 (from reference 14) 
 For acid leaching with 2 M HCl, approximately 100 mg of hair sample was put 
into a 50 mL polypropylene graduated centrifuge tube, and 5 mL of 2 M HCl were added. 
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The tubes were closed and shaken on a mechanical shaker for 4 hours. The tubes were 
then centrifuged at 2500 rpm for 20 minutes to separate the hair. The supernatant 
containing the methylmercury was transferred into a tarred 50 mL polypropylene 
centrifuge tube and diluted with DDI water to 20 mL. Four sample preparation replicates 
were prepared. 
 
Method 5 (from reference 15) 
 For cold acid digestion with 2 M HCl, to prepare four sample preparation 
replicates, approximately 200 mg of hair sample were weighed into four 50 ml 
polyproppylene graduated centrifuge tubes, and 5 mL of 2 M HCl were added to each 
tube. The tubes were closed and kept on the bench top for 24 hours. These tubes were 
then centrifuged at 2500 rpm for 20 minutes to separate the hair. The supernatants 
containing the methylmercury were transferred into tarred 50 mL polypropylene 
graduated centrifuge tubes and diluted with DDI water to 20 mL. 
 
Method 6 (from reference 16) 
 For acid leaching with 5 M HNO3, approximately 50 mg of hair sample was 
placed into a 15 mL disposable glass centrifuge tube with a snap on cap, to which 350 µL 
of 5 M HNO3 were added. The centrifuge tube was loosely capped and heated at 100
o
C in 
a water bath for 120 minutes. The sample solution was then stirred well using a vortex 
mixer and then centrifuged for 5 minutes at 3200 rpm. The cooled extract was transferred 
into a tarred 50 ml polypropylene centrifuge tube and diluted to 20 mL by adding DDI 
water. Four sample preparation replicates were completed. 
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Method 7 (from reference 17) 
 For cold acid digestion with concentrated HNO3 and 30% H2O2, approximately 
100 mg portions of the sample were weighed into four 15 ml centrifuge tubes; 2 mL of 
concentrated HNO3 and 1 ml of 30% H2O2 were added to each tube. The mixtures were 
then vortexed and kept on the bench top overnight. The next day, the mixtures were 
vortexed for 1 minute and then centrifuged for 5 minutes at 3500 rpm. The extracts were 
transferred into 50 ml polypropylene sample vials and diluted with DDI water to 20 ml. 
 
Results and Discussion 
 The certified value for total mercury in hair standard IAEA-085 is 23.2 ± 0.8 
ppm, and that for methylmercury is 22.9 ± 1.0 ppm. Table 1 shows the results obtained 
using the seven sample preparation methods described above from the literature and 
traditional external calibration with LC-ICP-MS. Concentrations are given in ppm, and 
results are reported at the 95 % C.I. The percent recoveries are given in the parentheses. 
 
Method [Hg
2+
] in ppm 
(as Hg) 
[CH3Hg
+ 
] in ppm (as 
Hg), percent 
recoveries in 
parentheses  
Sum of species (ppm), percent 
recoveries in parentheses  
certified 
value 
 22.9 ± 1.0 23.2 ± 0.8 
1 0.63 ± 0.18 20.10 ± 0.26 (88 ± 1) 20.73 ± 0.32 (89 ± 1) 
2 0.23 ± 0.02 19.88 ± 1.36 (87 ± 6) 20.11 ± 1.36 (87 ± 6) 
3 not detected 20.36 ± 1.05 (89 ± 5) 20.36 ± 1.05 (88 ± 5) 
4 0.27 ± 0.29 22.36 ± 0.86 (98 ± 4) 22.63 ± 0.91 (98 ± 4) 
5 not detected 18.38 ± 0.93 (80 ± 4) 18.38 ± 0.93 (79 ± 4) 
6 8.89 ± 0.69 12.83 ± 0.68 (56 ± 3) 21.72 ± 0.97 (94 ± 4) 
7 23.57 ± 0.78 1.62 ± 0.15 (7± 1) 25.19 ± 0.79 (109 ± 3) 
 Table 1 – results from mercury species analysis using literature methods 
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 As can be seen in Table 1, there appears to have been a significant amount of 
conversion of CH3Hg
+
 to Hg
2+
 in methods 6 and 7, much more so than in the other five 
methods. It is interesting to note that the latter two methods involved the usage of HNO3 
along with either an elevated temperature (100
O
C for 2 hours) or a relatively long 
reaction time (overnight, ~ 16 hours), whereas the other five methods used HCl instead of 
HNO3.  It was also observed that, with the exception of method 4, the percent recovery of 
CH3Hg
+
 was less than 100%. With respect to methods 1, 2, 3, and 5, this result was most 
likely due to incomplete extraction of the CH3Hg
+
; for methods 6 and 7, this result was 
likely due, as mentioned above, to the conversion of CH3Hg
+
 to Hg
2+
. 
 The results in table 1 clearly indicate the importance of accounting for both 
species interconversion and sample recovery, as failure to do so would decrease the level 
of confidence that one has in the final reported results. SIDMS is designed to address 
both of these issues. In addition, for field applications, a sample preparation method 
involving the equilibration of natural abundant and enriched analytes on a solid phase 
extraction (SPE) column for the purpose of using SIDMS technology would be useful as 
well so that, if unstable analytes partially decompose or interconvert with other analytes 
before they reach the laboratory, EPA Method 6800A will correct for the transformations. 
The next section describes experiments used to demonstrate these applications  as they 
pertain specifically to hair mercury speciation. 
 
2 A ii – Analysis of Mercury Species in hair using SIDMS with iSPIKE Methodology 
 In his 2006 PhD dissertation, David Lineman described the procedure of loading  
an SPE column with an isotopically enriched analyte and then loading that same column 
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at some later time with the natural abundant analyte such that equilibration between the 
former and latter analytes occurred on the column.  At that time, only the GC-MS 
application of this concept was implemented and described.  It had been envisioned to 
follow up on this concept with LC-MS or other types of mass spectrometry applications 
to investigate the general application of this novel method of IDMS equilibration and 
spiking. Following elution, mass spectrometry analysis of the eluent would enable one to 
implement a new type of novel, complete IDMS analysis (18). This procedure is known 
as the iSpike ® method (registered trademarked of Applied Isotope Technologies, AIT, 
the “i” refers to “isotope”), and is especially applicable to field sample preparation. It also 
has been envisioned for clinical and homeland defense applications and patent are 
pending on these applications. To follow up on this work, an experiment was completed 
involving the speciation of mercury in hair. In this experiment, an attempt to achieve 
equilibration between the natural abundant and enriched mercury species on a specialized 
SPE column was made, and the results using that sample preparation method were 
compared to those from a method in which equilibration occurred in a microwave vessel. 
This experiment is described below.  
 
Materials and Methods  
Reagents/standards:  
 The hair standard used was certified reference material (IAEA – 085) from the 
International Atomic Energy Agency (Vienna, Austria) that was certified for total 
mercury and CH3Hg
+
 . The water used for solutions was double deionized (DDI) water 
from a Barnstead NANOpure Ultrapure Water System (Dubuque, IA).  Reagent grade 
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nitric acid and L-cysteine were obtained from Fisher Scientific (Pittsburgh, PA). Nitric 
acid was purified using sub-boiling distillation in a quartz still (Milestone, Monroe, CT). 
Isotopically enriched 
199
Hg
2+
 and CH3
200
Hg
+
 and sulfhydryl cotton fiber SPE were 
obtained from Applied Isotope Technologies, Inc. (Pittsburgh, PA). 
 
Instrumentation/analytical methods: 
 For microwave sample preparation, a Milestone (Monroe, CT) Ethos 1600 
microwave system was used. This system was equipped with temperature feedback 
control and magnetic stirring, as well as high pressure (maximum pressure – 100 bar) 
closed vessel microwave vessels made of high purity TFM (a thermally resistant form of 
fluoropolymer) with a capacity of 100 ml.  
For analysis of the prepared samples, direct analysis of the SPE eluents were 
made with an Agilent 4500 ICP-MS (Agilent Technologies, Palo Alto, CA).  
Quantification was performed by monitoring the 
199
Hg, 
200
Hg, and 
202
Hg isotopes for both 
the eluent with the Hg
2+
 and that with the CH3Hg
+
, and the equations described in chapter 
1 were used for SIDMS analysis.  For each sample preparation method, three sample 
preparation replicates and four analysis replicates were completed (n=12). The isotope 
ratios were corrected for dead time, and a solution with natural abundant Hg
2+
 and 
CH3Hg
+
 was also analyzed periodically between samples to obtain the mass bias 
correction factor. 
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Sample preparation Method A – equilibration of natural abundant and enriched 
analytes in the microwave vessel 
 Procedures described in EPA Method 3200 (19) were used for this experiment. To 
three microwave vessels were each added a stir bar, 100 mg of certified reference 
material hair (IAEA-085), known amounts of 
199
Hg
2+
 and CH3
200
Hg
+
, and 10 ml of 4 M 
HNO3. To a fourth vessel were added everything that was in the other three except the 
hair standard in order to serve as a procedural blank. Microwave irradiation was applied 
to the samples with stirring (2 minute ramp to 100
O
C, 10 minute hold at 100
O
C). After 
cooling, each sample was filtered through a 0.22 µm glass filter. To each sample were 
then added 2 mL of 0.2 M of pH 3.0 acetate buffer, followed by enough 10 N NaOH to 
adjust the pH of the sample solution to ~ 3 – 4.  
For SPE, four sulfhydryl cotton fiber SPE columns were conditioned with 10 mL 
of H2O, then 10 mL of 6 N HCl, and lastly 15 mL of H2O. The pH adjusted samples were 
applied to the columns, and 8 ml of a solution containing 1.0 M HCl and 1.0 M NaCl 
were run through each column, followed by 2 mL of H2O. The eluents were collected and 
referred to as “eluent 1a, 1b,” etc.  Another 8 mL of a solution consisting of 6M HCl, 
saturated NaCl, and 0.1% CuCl2·2H2O were applied to each column, followed by 2 mL 
of H2O, and the eluents from the application of this solution was collected as well 
(referred to as “eluent 2a, 2b,”etc.). 
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Sample Preparation Method B – Equilibration of natural abundant and enriched 
analytes on the SPE column   
 The samples were prepared exactly the way they were in method A except that no 
199
Hg
2+
 and CH3
200
Hg
+
 were added to the microwave vessel; instead, they were added to 
the conditioned SPE columns. After implementing the microwave protocol and  adjusting 
the pH of the samples to ~ 3 – 4 with the acetate buffer and the 10 N NaOH, the samples 
were applied to the conditioned and double spiked columns, and the eluents were 
collected just like in method A.   
 
Results and Discussion 
 The CH3Hg
+
, which was less strongly adsorbed to the stationary phase than Hg
2+
, 
was detected in eluent 1, and the Hg
2+
, more strongly adsorbed to the stationary phase, 
was detected in eluent 2. The reason for this difference in adsorption strength can be seen 
in the schematic representation of the interaction between these analytes and the 
stationary phase shown in Figures 1 and 2 below: 
SHgH3C
 
Figure 1 – Interaction between CH3Hg
+
 and the stationary phase – weaker adsorption due 
to analyte bonding to only one Sulfur on the stationary phase 
 
SHgS
 
Figure 2 – Interaction between Hg2+ and the stationary phase – stronger adsorption due to 
analyte bonding to two Sulfurs on the stationary phase 
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 The results from the analysis of the mercury speciation in hair using methods A 
and B are shown in Table 2 (values reported at 95% C.I.): 
 Hg
2+
 concentration 
in ppm 
CH3Hg
+
 
concentration in 
ppm 
Sum of Species in 
ppm 
Certified value  22.9 ± 1.2 23.2 ± 0.8 
Method A – 
equilibration in the 
microwave vessel 
1.617 ± 0.104 22.698 ± 0.990 23.315 ± 0.995 
Method B – 
equilibration on 
the SPE column 
1.400 ± 0.092 22.766 ± 1.301 24.166 ± 1.304 
Table 2 – Mercury Speciation in hair using equilibration in the microwave vessel and 
equilibration on the SPE column 
 
The results from the mercury speciation in hair using methods A and B were 
consistent with each other as well as with the certified values. These results demonstrate 
the usefulness of SIDMS for mercury speciation as well as the fact that equilibration 
between natural abundant and isotopically enriched mercury species can occur on the 
SPE column. This equilibration enables one to obtain the correct concentration of the 
analytes, even if the recovery is less that 100%. This is because the “apparent” recovery 
remains the same (i.e. if the recovery of the natural abundant analyte is 80%, that of the 
enriched analyte will also be 80%, so the ratio of the former to the latter will remain 
constant).  Later on in this chapter, an experiment mimicking a 25% reduction in 
recovery of the analytes of interest will be described to demonstrate these concepts 
further. 
 As mentioned earlier, a method capable of analyzing C2H5Hg
+
 in addition to Hg
2+
 
and CH3Hg
+
 would be useful. In the next section is a description of an experiment in 
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which these three mercury species are interconverting, and a set of equations based on 
work done by Dr. Rahman, which are contained in his dissertation (20) and were referred 
to in the previous chapter, were used to quantitatively successfully determine the 
concentrations of the three mercury species. These equations are an extension of the two species 
equations shown earlier, and are available in the literature from the Kingston Research Group in 
several publications and presentations.  
 
2 A iii – Analysis of three Mercury Species in Hair using SIDMS 
 As mentioned on p. 17, there is documented evidence of ethylmercury being 
detected in hair (6,7) and blood (7). To expand upon this work which is already in the 
literature, an experiment was carried out to demonstrate how SIDMS can correct for 
interconversions among mercury species, such as C2H5Hg
+
, Hg
2+
 and CH3Hg
+
 during 
sample preparation and/or analysis. This experiment is described next. 
 
Materials and Methods 
Reagents/standards:  
 The hair standard used was certified reference material (IAEA – 085) from the 
International Atomic Energy Agency (Vienna, Austria) that was certified for total 
mercury and CH3Hg
+
. The water used for solutions was double deionized (DDI) water 
from a Barnstead NANOpure Ultrapure Water System (Dubuque, IA).  Reagent grade 
nitric acid and L-cysteine were obtained from Fisher Scientific (Pittsburgh, PA). Nitric 
acid was purified using sub-boiling distillation in a quartz still (Milestone, Monroe, CT).  
A solution of known concentration of C2H5Hg
+
 was supplied by Applied Isotope 
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Technologies (Pittsburgh, PA). Isotopically enriched 
199
Hg
2+
,CH3
200
Hg
+
 and C2H5 
201
Hg
+
 
were also supplied by Applied Isotope Technologies. 
 
Instrumentation/analytical methods: 
 For microwave sample preparation, a Milestone (Monroe, CT) Ethos 1600 
microwave system was used. This system was equipped with temperature feedback 
control and magnetic stirring, as well as high pressure (maximum pressure – 100 bar) 
closed vessel microwave vessels made of high purity TFM (a thermally resistant form of 
fluoropolymer) with a capacity of 100 mL. 
 For analysis of the prepared samples, LC-ICP-MS analysis was performed using 
isocratic elution with a Waters (Milford, MA) Novapak C18 reversed phase column (150 
x 3.9 mm, 4 µm) and a 709 IC polymeric inert pump with an 838 advanced sample 
processor for automatic sample delivery from Metrohm Peak (Houston, TX) coupled to 
an Agilent 4500 ICP-MS (Agilent Technologies, Palo Alto, CA). The mobile phase 
consisted of 0.2% cysteine. The flow rate was 1.0 mL/min, and the injection volume was 
100 µl. The chromatography and automation equipment were situated in a high efficiency 
particulate air (HEPA) filter class 100 clean hood chamber next to the ICP-MS in a class 
1000 clean room laboratory. Quantification was performed by monitoring the 
199
Hg, 
200
Hg, 
201
Hg and 
202
Hg isotopes for the Hg
2+
, CH3Hg
+
, and C2H5Hg
+
 peaks in the 
chromatograms, and isotope ratios for SIDMS analysis were based upon peak area ratios. 
Two sample preparation replicates and four analysis replicates were completed (n = 8). 
The isotope ratios were corrected for dead time, and a solution with natural abundant 
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Hg
2+
, CH3Hg
+
, and C2H5Hg
+
 was also analyzed periodically between samples to obtain 
the mass bias correction factors. 
 
Sample Preparation 
 To a microwave vessel were added  a stir bar and 50 mg of IAEA-085 hair 
standard, and this hair was spiked with a known amount of natural abundant 
ethylmercury to mimic a hair sample with three mercury species instead of two. To the 
vessel were then added known amounts of 
199
Hg
2+
, CH3
200
 Hg
+
, and C2H5
201
Hg
+
, along 
with 10 mL of 4M HNO3. Microwave irradiation was implemented following the 
protocol described in EPA Method 3200 (14) with a 2 minute ramp to 100
O
C, followed 
by a10 minute hold at 100
O
C. After filtration through a 0.22 µm filter, the sample was 
analyzed by LC-ICP-MS as described above. Sample preparation was done in duplicate, 
with 4 analysis replicates for each sample preparation replicate (n=8). Procedural blanks 
that included everything except the certified hair standard and spiked natural abundant 
C2H5Hg
+
  were prepared and analyzed in a likewise manner. 
Results and Discussion 
 The results from the SIDMS analysis of the three mercury species in hair are 
shown in Table 3 (results reported in units of ppm at 95% C.I.):
   
3
3   
 Hg2+ CH3Hg
+ C2H5Hg
+ % conv. 
of Hg2+ 
to 
CH3Hg
+ 
% conv. 
of 
CH3Hg
+ 
to Hg2+ 
% conv. 
of 
CH3Hg
+ 
to 
C2H5Hg
+ 
% conv. 
of 
C2H5Hg
+ 
to 
CH3Hg
+ 
% conv. 
of 
C2H5Hg
+ 
to Hg2+ 
% conv. 
of Hg2+ 
to 
C2H5Hg
+ 
Certified 
Value 
 22.9 ± 
1.4 
* NA NA NA NA NA NA 
SIDMS 
measured 
1.30 ± 
0.74 
22.06 ± 
0.44 
21.10 ± 
1.0 
8.29 ± 
0.87 
5.36 ± 
0.84 
1.73 ± 
0.33 
6.78 ± 
0.68 
74.31 ± 
4.03 
1.21 ± 
0.42 
* Not present originally, spiked so as to obtain 22.7 ppm ± 1% RSD 
Table 3 – Results - analysis of Hg2+, CH3Hg
+
, and C2H5 
201
Hg
+
 in spiked hair standard
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 The expected values were obtained despite the interconversions among the 
mercury species, particularly the conversion of C2H5Hg
+
 to Hg
2+
 (over 70% conversion).  
These results demonstrate the usefulness of the SIDMS method for correcting for species 
interconversions so as to enable one to obtain the original analyte concentrations. In this 
context, the specific application was for mercury speciation in hair.  The method can also 
be used for the determination of mercury species in other matrices as well, one of them 
being blood. This application of SIDMS to mercury speciation in blood is described in 
the next section. 
 
2B – Mercury Speciation in blood 
 As in hair, normally, most of the mercury in blood is in the form of 
methylmercury. The analysis of mercury species in blood is somewhat more challenging 
than it is in hair, however, due to the lower concentration of mercury in blood, as 
literature values for the hair to blood mercury ratio have been found to be between 140 
and 370 (21). According to the EPA, blood mercury levels are commonly below a level 
associated with possible health effects, 5.8 µg/ml (about 6 ppb) (22). Over the years, 
methods for analyzing mercury species in blood have included isotope dilution with 
alkaline digestion and sodium tetraethylborate derivatization combined with gas 
chromatography/ICP/MS (GC/ICP/MS) analysis (23) as well as ultrasound extraction 
combined with LC/ICP/MS analysis with quantification based on external calibration (9). 
SIDMS can expand upon existing methods like these by taking into account both sample 
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recovery and species interconversion. Experiments designed to demonstrate this concept 
are described in the next section. 
 
2B i – Analysis of Mercury Species in Blood with Elevated Mercury Concentration 
Materials and Methods 
 
Reagents/Standards 
 The human blood sample used was obtained from the Stanford University blood 
bank and was screened for the absence of Hepatitis B and HIV before being sent to 
Duquesne University. The sample included EDTA as an anticoagulant and, after arriving 
at Duquesne, was stored at -20
o
C until usage. Reagent grade nitric acid and L-cysteine 
were obtained from Fisher Scientific (Pittsburgh, PA). Isotopically enriched 
199
Hg
2+
 and 
CH3
200
Hg
+
 were obtained from Applied Isotope Technologies, Inc. (Pittsburgh, PA). 
 
Instrumentation/analytical methods: 
 For microwave sample preparation, a Milestone (Monroe, CT) Ethos 1600 
microwave system was used. This system was equipped with temperature feedback 
control and magnetic stirring, as well as high pressure (maximum pressure – 100 bar) 
closed vessel microwave vessels made of high purity TFM (a thermally resistant form of 
fluoropolymer) with a capacity of 100 mL. 
 For total mercury analysis, a DMA-80 from Milestone (Monroe, CT) was used by 
following the guidelines stated in EPA Method 7473 (24). This instrument analyzes a 
sample, such as a blood sample, directly without need of sample preparation by thermally 
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decomposing it at 750
o
C such that all of the mercury species are converted to elemental 
mercury vapor. This mercury vapor then binds to and is subsequently released by a gold 
amalgamator, after which it is analyzed by atomic absorption mass spectrometry.  
For analysis of the samples for mercury speciation, LC-ICP-MS analysis was 
performed using isocratic elution with a Waters (Milford, MA) Novapak C18 reversed 
phase column (150 x 3.9 mm, 4 µm) and a 709 IC polymeric inert pump with an 838 
advanced sample processor for automatic sample delivery from Metrohm Peak (Houston, 
TX) coupled to an Agilent 4500 ICP-MS (Agilent Technologies, Palo Alto, CA). The 
mobile phase consisted of 0.2% cysteine. The flow rate was 1.0 mL/min, and the 
injection volume was 100 µl. The chromatography and automation equipment were 
situated in a high efficiency particulate air (HEPA) filter class 100 clean hood chamber 
next to the ICP-MS in a class 1000 clean room laboratory. Quantification was performed 
by monitoring the 
199
Hg, 
200
Hg and 
202
Hg isotopes for the Hg
2+
and CH3Hg
+
peaks in the 
chromatograms, and isotope ratios for SIDMS analysis were based upon peak area ratios. 
Sample preparation was done in triplicate, and four analysis replicates were completed 
for each sample preparation replicate (n=12). The isotope ratios were corrected for dead 
time, and a solution with natural abundant Hg
2+
 and CH3Hg
+
 was also analyzed 
periodically between samples to obtain the mass bias correction factors. 
 
Sample preparation  
The Stanford blood sample was tested for total mercury with the DMA-80 and 
found to have a concentration of 2.70 ± 0.76 ppm. This sample was then spiked with 
natural abundant Hg
2+
 and CH3Hg
+
 to represent a blood sample with a total mercury 
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concentration of ~ 400 ppb. Although this value is much higher than what a normal 
human blood sample would have (less than 5 µg/l, or ~ 5 ppb) (25), cases in which blood 
mercury concentrations in the triple or quadruple digits ppb have been documented. For 
example, Dr. Nilo Arnaiz from the UCLA Department of Medicine reported a case in 
which a 37 year old woman who consumed swordfish daily and ended up with symptoms 
of mercury poisoning as a result had a blood mercury concentration of 208 µg/l 
(approximately 200 ppb) (26). Another case was reported in which a 48 year old man 
deliberately consumed a solution of inorganic mercury salt and ended up in the hospital 
with mercury poisoning and a blood mercury concentration of 5,200 µg/l (25).  
For mercury speciation, to three microwave vessels were each added 0.6000g of 
the blood with the elevated mercury, known amounts of 
199
Hg
2+
 and CH3 
200
Hg
+
, and 10 
ml of 4M HNO3. To a fourth vessel was added everything that was added to each of the 
other three except the blood so as to serve as a procedural blank. Microwave irradiation 
was applied to the samples according to the protocol described in EPA Method 3200 (19) 
(2 minute ramp to 100
o
C, 10 minute hold at 100
o
C). After cooling, the samples were 
filtered through a 0.22 µm filter, then stored at 4
o
C until analysis.   
To mimic what would happen in case of a 25% reduction in recovery, aliquots 
were taken from the microwave prepared triplicate samples and diluted 25% with 4M 
HNO3. These samples were analyzed using LC-ICP-MS using conditions similar the ones 
described earlier in this chapter for the hair studies.  
 
Results and discussion 
The results obtained from the SIDMS analyses of both the originally prepared 
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samples and the ones prepared so as to mimic a 25% reduction in recovery are shown in 
table 4 below (concentrations reported at the 95% C.I.): 
 
 
 Hg2+ conc. in 
ppb 
CH3Hg
+ conc. 
in ppb 
Sum of Hg2+ 
and CH3Hg
+ in 
ppb 
Hg2+ to 
CH3Hg
+ 
CH3Hg
+ to 
Hg2+ 
Original 
Sample 
220 ± 11 168 ± 9 388 ± 16 1.08% ± 3.01% 
 
1.50% ± 1.55% 
 
Sample 
mimicking 
25% reduction 
in recovery 
218 ± 9 161 ± 11 379 ± 17 2.02% ± 2.74% 
 
0.14% ± 2.06% 
 
Table 4 – Results from analysis of Hg+ and CH3Hg
+
 in spiked Stanford blood sample 
 
The elevated mercury sample was also analyzed for total mercury using EPA method 
7473 as described earlier. The result obtained was 402 ± 39 ppb, which is in agreement 
with the results from sum of the mercury species in the SIDMS analyses shown above; 
therefore, mass balance was achieved. 
Despite the fact that the second set of samples were prepared so as to mimic a 
25% reduction in recovery when compared to the original samples, SIDMS analysis 
yielded the same results for Hg
2+
 and CH3Hg
+
 concentrations from both sets of samples. 
This is because the calculations for the concentrations were based, not upon calibration 
curves, but upon isotopic ratios which remain constant regardless of the percentage 
recovery or the intensity of the signal coming from the mass spectrometer.  
Since most human blood samples have mercury species concentrations below 10 
ppb, for improved sensitivity, gas chromatography, rather than liquid chromatography, is 
often used with ICP-MS for this type of analysis (although, as mentioned earlier, an LC-
Interconversion % 
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ICP-MS method for speciation of mercury in blood has been published – see reference 
number 9). A description of mercury speciation analysis in blood using LC-ICP-MS was 
described in this section; the next section describes the same kind of analysis using 
SPME-GC-ICP-MS. 
 
2B ii – Analysis of Mercury Species in Blood by SPME-GC-ICP-MS using SIDMS 
 
Reagents/Standards 
The blood standard used was SRM 966 level 2 bovine blood from the National 
Institute of Standards and Technology (NIST, Gaithersburg, MD). This blood standard 
was certified for total mercury and had reference values (values not certified due to all of 
the potential biases not being accounted for) for inorganic mercury and methylmercury. 
The water used for solutions was double deionized (DDI) water from a Barnstead 
NANOpure Ultrapure Water System (Dubuque, IA).  Reagent grade nitric acid was 
obtained from Fisher Scientific (Pittsburgh, PA). Isotopically enriched 
199
Hg
2+
 and 
CH3
200
Hg
+
 were obtained from Applied Isotope Technologies, Inc. (Pittsburgh, PA). 
Sodium tetrapropylborate was obtained from ABCR (Karlsrue, Germany).  
 
Instrumentation/analytical methods: 
 For microwave sample preparation, a Milestone (Monroe, CT) Ethos 1600 
microwave system was used. This system was equipped with temperature feedback 
control and magnetic stirring, as well as high pressure (maximum pressure – 100 bar) 
closed vessel microwave vessels made of high purity TFM (a thermally resistant form of 
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fluoropolymer) with a capacity of 100 mL. Quartz vessels (20 ml) were also used for 
implementation of the vessel within a vessel system (to be described in further detail in 
the sample preparation section). 
 For mercury speciation analysis of the prepared samples, SPME-GC-ICP-MS was 
used. The SPME equipment consisted of an 85 µm Carboxen/PDMS fiber assembly (part 
number 57334-U, Supelco, subsidiary of Sigma-Aldrich, St. Louis, MO),  a Micro-
Extraction holder (part number 57330-U, Supelco, subsidiary of Sigma-Aldrich, St. 
Louis, MO), and 20 ml borosilicate glass headspace vials with septa caps (part number 
S326-0020, I-CHEM, Rockville, TN). The GC-ICP-MS system consisted of an Agilent 
5890 GC connected through a transfer line to an Agilent 4500 ICPMS, and the column 
used was an Agilent DB-5, 30 m x 0.25 mm x 0.25 μm (Agilent p/n 122-5032). The 
injection port temperature was 150 
o
C, and the temperature gradient consisted of an initial 
2 minute hold at 60 
o
C, followed by an increase from 60
o
C to 120
o
C (15
o
C/minute), then 
and increase from 120
o
C to 200
o
C (20
o
C/minute), and, lastly, a two minute hold at 200
o
C. 
Quantification was performed by monitoring the 
199
Hg, 
200
Hg, and 
202
Hg isotopes for the 
Hg
2+
 and CH3Hg
+ 
peaks in the chromatograms, and isotope ratios for SIDMS analysis 
were based upon peak area ratios. Three sample replicates and three analysis replicates 
were completed (n=9). A solution with natural abundant Hg
2+
and CH3Hg
+
was also 
analyzed periodically between samples to obtain the mass bias correction factors. 
 
Sample Preparation 
To a quartz microwave vessel were added a Teflon stir bar, 0.300g of SRM 966 
level 2 Bovine blood (certified value for total Hg concentration = 29.8 ± 1.6 ppb, 0.0350g 
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of 22.311 ppb 
199
Hg
2+
 0.0350g of 24.374 ppb CH3
200
Hg
+
 , and 7.2 g of 2 M HNO3. For 
the analytical blank, 0.300g of H2O was used in place of the blood. The small vessel was 
put into a larger Teflon vessel with 10 mL of 2 M HNO3, and the vessel was subjected to 
microwave irradiation (2 minute ramp to 100
o
C, 10 minute hold at 100
o
C). After cooling, 
the contents of the vessel were transferred to a centrifuge tube and were centrifuged to 
separate particulate matter from the extract. 2 g of the extract were combined with 8 g of 
pH 5.2 ammonium acetate buffer (0.287M acetic acid, 0.710M ammonium acetate) and 
100 mg of sodium tetrapropylborate in a 20 mL vial (for derivatization). This solution 
was stirred at room temperature for ~3 – 5 minutes, after which the SPME fiber (85 μm 
Carboxen/PDMS) was inserted into the headspace, and the solution was stirred at 65
o
C 
for 15 minutes. The SPME was then inserted into the GC-ICP-MS for analysis. Sample 
preparation was done in triplicate, as was the analysis (n = 9). 
 
Results and discussion 
 The results from the mercury speciation analysis of SRM 966 level 2 are shown in 
Table 5 (results reported at 95% C.I.): 
 
Experimental 
Hg
2+
 conc. 
(ppb) 
Experimental 
CH3Hg
+
 
conc. (ppb) 
Conversion 
of CH3Hg
+
 
to Hg
2+ 
Conversion 
of Hg
2+
 to 
CH3Hg
+ 
Experimental 
sum of Hg 
species (ppb) 
Certified 
value for 
total Hg 
(ppb) 
16.7 ± 1.2 15.3 ± 1.5 4% 3% 31.9 ± 2.1 29.8 ±1.6 
Table 5 – Results from SIDMS analysis of Hg species in SRM 966 level 2 blood 
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The experimental value obtained for the sum of the mercury species (31.9 ± 2.1 ppb) was 
in agreement with the certified value for total mercury in SRM 966 level 2 blood (29.8 
±1.6 ppb).  
 
Future work  
 Further work on the speciation of three mercury species (Hg
2+
, CH3Hg
+
, and 
C2H5Hg
+
) in blood will be carried out by our research group using SRM 955c level 3 
Caprine blood from NIST as a standard, as this standard is certified for the three mercury 
species mentioned, as well as total mercury.  Preliminary work has already been done 
with blood samples from Stanford University that were spiked with Hg
2+
, CH3Hg
+
, and 
C2H5Hg
+
 after they arrived at Duquesne University. The chromatogram from one of these 
samples in which the final concentration of each species in the blood was ~ 30 ppb is 
shown in Figure 3 (signal from 
202
Hg): 
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Figure 3 – Three mercury species measured by SPME-GC-ICP-MS 
 
Preliminary evidence suggests that a significant percentage of the organic mercury 
species converted to Hg
2+
 during the measurement; however, the SIDMS technology can 
correct for these transformations. Additionally, to improve sensitivity, more advanced 
instrumentation will be used – specifically, an Agilent 7890A GC with an Agilent 7700 
ICP-MS. 
 So far, this chapter has focused on the analyses of mercury species in human 
biological matrices to assess toxicological exposure. The methods described in this 
chapter can also be used for mercury speciation in environmental samples which can be 
potential sources of that exposure. One such matrix for which mercury speciation using 
EPA Method 6800 has already been successfully used is soil (27). Another environmental 
matrix for which mercury speciation would be important is crude oil, and the usage of 
SIDMS for such an analysis is described in the next section. 
 
2C – Mercury Speciation in Crude Oil 
 The analysis of mercury species in crude oil is important not only for the purpose 
of assessing the impact that the oil producers have on the environment, but also for 
determining how best to handle the problems associated with mercury species being 
present in the equipment used to process the oil. For example, elemental mercury can 
form amalgams with certain metals in equipment made from those metals and damage 
that equipment as a result (28).  
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 Our research group obtained two crude oil samples from a major oil company and 
analyzed them for total mercury and mercury species extractable by EPA Method 3200. 
The description of the procedures used for these analyses is described next. 
 
2C i – Total Mercury and Mercury Speciation in Crude Oil  
Reagents/standards:  
 The water used for solutions was double deionized (DDI) water from a Barnstead 
NANOpure Ultrapure Water System (Dubuque, IA).  Reagent grade nitric acid, L-
cysteine, hydrogen peroxide, pyridine, and methanol were obtained from Fisher Scientific 
(Pittsburgh, PA). Nitric acid was purified using sub-boiling distillation in a quartz still 
(Milestone, Monroe, CT).  Isotopically enriched 
199
Hg
2+
, CH3
200
Hg
+
, and C2H5
201
Hg were 
supplied by Applied Isotope Technologies (Pittsburgh, PA). The two crude oil samples 
were obtained from a major oil company. 
 
Instrumentation/analytical methods: 
 For microwave sample preparation, a Milestone (Monroe, CT) Ethos 1600 
microwave system was used. This system was equipped with temperature feedback 
control and magnetic stirring, as well as high pressure (maximum pressure – 100 bar) 
closed vessel microwave vessels made of high purity TFM (a thermally resistant form of 
fluoropolymer) with a capacity of 100 mL. 
For total mercury analysis of the prepared samples, direct analysis was made with 
an Agilent 4500 ICP-MS (Agilent Technologies, Palo Alto, CA).  Quantification was 
performed by monitoring the 
199
Hg  and 
202
Hg isotopes for IDMS analysis. Three sample 
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preparation replicates and four analysis replicates were made for each of the two crude oil 
samples.  
For analysis of the EPA 3200 extractable mercury species, LC-ICP-MS analysis 
was performed using isocratic elution with a Metrohm Peak (Houston, TX) PS-DVB C18 
reversed phase column (150 x 4.6 mm, 2 µm) and a model 818 IC polymeric inert pump 
with an 838 advanced sample processor for automatic sample delivery from Metrohm 
Peak coupled to an Agilent 4500 ICP-MS (Agilent Technologies, Palo Alto, CA). The 
mobile phase consisted of a pH 3 solution of 50 mmol/L pyridine, 0.5% (w/v) L-cysteine, 
and 5% (v/v) methanol. The flow rate was 1.0 mL/min, and the injection volume was 100 
µl. The chromatography and automation equipment were situated in a high efficiency 
particulate air (HEPA) filter class 100 clean hood chamber next to the ICP-MS in a class 
1000 clean room laboratory. Quantification was performed by monitoring the 
199
Hg, 
200
Hg, 
201
Hg and 
202
Hg isotopes for the Hg
2+
, CH3Hg
+
, and C2H5Hg
+
 peaks in the 
chromatograms, and isotope ratios for SIDMS analysis were based upon peak area ratios. 
Three sample preparation replicates and four analysis replicates were completed. The 
isotope ratios were corrected for dead time, and a solution with natural abundant Hg
2+
, 
CH3Hg
+
, and C2H5Hg
+
 was also analyzed periodically between samples to obtain the 
mass bias correction factors. Three sample preparation replicates and four analysis 
replicates were made for each of the two crude oil samples (n=12). 
 
Sample Preparation for total Hg analysis 
 To a microwave vessel were added a stir bar, 0.5 g of crude oil, a known amount 
of 
199
Hg
2+
, 9 mL of HNO3, and 2 mL of 30% H2O2. The sample was subjected to 
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microwave irradiation using EPA 3052 (29) (ten minute ramp to 180
o
C, ten minute hold 
at 180
o
C). After cooling, the sample was filtered through a 0.22 mm glass fiber filter and 
then stored at 4
o
C until analysis. Sample preparation was done in triplicate, and two 
procedural blanks containing everything that was in the crude oil sample preparation 
replicates except the crude oil itself were also prepared.  
 
 Sample Preparation for analysis of Hg species extractable by EPA Method 3200 
 To a microwave vessel were added a Teflon stir bar, 0.5 g of crude oil, known 
amounts of 
199
Hg
2+
, CH3
200
Hg
+
, and C2H5
201
Hg, and 10 mL of 4 M HNO3. The sample 
was subjected to microwave irradiation using EPA Method 3200 (19) (two minute ramp 
to 100
o
C, ten minute hold at 100
o
C). After cooling, there was a mixture of aqueous 
solution and oily residue. The aqueous part of the sample was removed and filtered 
through a 0.22 mm glass fiber filter, diluted to 20 mL with DDI water, and then stored at 
4
o
C until analysis. Sample preparation was done in triplicate, and two procedural blanks 
containing everything that was in the crude oil sample preparation replicates except the 
crude oil itself were also prepared. 
 
Sample preparation for nonextractable Hg Species 
 The microwave vessels with the oily residues were spiked with known amounts of 
199
Hg
2+
, and to each of them were also added 9 mL of concentrated HNO3 and 1 mL of  
30% H2O2. EPA Method 3052 was implemented (ten minute ramp to 180
o
, ten minute 
hold at 180
o
). After cooling and filtering the samples through the 0.22 mm glass fiber 
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filters, the samples were stored at 4
o
C until analysis. A procedural blank was also 
prepared with the samples. 
 
Results and Discussion 
 The total mercury results, extractable mercury species results, and total mercury 
results for the oily residues are shown in tables 6, 7, and 8, respectively, on the next page 
(results reported at the 95% C.I.):
   
4
8 
Crude oil sample Total Hg concentration in ppb 
Serial # 871833 414.1 ± 24.7 
Serial # 870987 432.8 ± 25.4 
Table 6 – Total Hg results in Crude Oil 
 
 
Table 7 – Extractable Hg Species 
 
Sample Total nonextractable Hg (ppb) 
Serial # 871833 342.5 ± 46.8 
Serial # 870987 323.9 ± 30.7 
Table 8 – Nonextractable Hg 
Sample 
 
Deconvoluted concentration 
(ppb) 
 
Interconversion % 
 Hg2+ CH3Hg
+ 
C2H5Hg
+
 Hg
2+
 to 
CH3Hg
+ 
CH3Hg
+
 
to Hg
2+
 
CH3Hg
+
 
to 
C2H5Hg
+
 
C2H5Hg
+
 
to 
CH3Hg
+
 
C2H5Hg
+
 
to Hg
2+
 
Hg
2+
 to  
C2H5Hg
+
 
Serial # 
871833 
17.3 
± 3.6 
0.8 ± 0.5 10.7 ± 1.1 9.6 ± 0.9 2.9  ± 0.8 0.8 ± 0.1 6.1 ± 0.6 55.1 ± 0.2 2.1 ± 1.0 
Serial # 
870987 
23.6 
± 3.7 
0.5 ± 0.1 7.4 ± 2.2 7.4 ± 1.0 6.2 ± 1.0 0.9 ± 0.1 7.9 ± 0.8 86.9 ± 0.5 1.3 ± 0.1 
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 In both crude oil samples, the extractable mercury species constituted about 7% of 
the total mercury in the sample. Further research is needed to determine the 
nonextractable mercury species. As with ethylmercury in hair, there was a significant 
amount of conversion of ethylmercury to inorganic mercury indicated in the speciation 
results. SIDMS successfully corrected for this conversion.  
 
2D - Conclusion 
 The focus of this chapter has been the analysis of mercury species in several 
different matrices.  Results showed that EPA Method 6800A could correct for 
interconversion among mercury species, as well as recoveries of less than 100%. A 
critical molecule which the body makes to combat the mercury species mentioned in this 
chapter, as well as other xenobiotics, is GSH. This molecule will be the focus of the next 
chapter. 
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Chapter 3 – Glutathione Speciation 
 
GSH is a tripeptide occurring in most cells of the body, and is involved in several 
critical functions, such as antioxidation and heavy metal detoxification (1). Under 
conditions of oxidative stress, the active form of GSH, reduced GSH forms a disulfide 
dimer, thereby producing GSSG. It has been discussed in the literature that an important 
biomarker may be the GSH/GSSG ratio associated with one’s level of oxidative stress, 
with lower values for the GSH/GSSG ratio indicating greater oxidative stress levels (2). It 
has been observed that children with autism have lower plasma GSH/GSSG ratios, as 
well as lower plasma total GSH (tGSH) concentrations compared to healthy controls (3). 
Abnormal GSH metabolism has been implicated in other conditions as well, such as 
AIDS and diabetes (4). 
 Several analytical methods have been developed for the analysis of tGSH, GSH, 
and GSSG. For tGSH analysis, methods have included spectrophotometric assays (5) as 
well as hyphenated techniques, such as LC separation combined with either 
electrochemical, fluorescence (6), or mass spectrometry detection (7). Prior to tGSH 
analysis, sample preparation typically involves treating disulfide bonds with a reducing 
agent, such as dithiothreitol (DTT) (8).  For analysis of GSH and GSSG, methods have 
included LC separation with either fluorescence or mass spectrometry detection (9). A 
derivatization agent, such as NEM, is often used during sample preparation to block the 
thiol group on GSH, thereby preventing its conversion to GSSG (10). 
 In quantitative analysis of tGSH, GSH, and GSSG, the traditional calibration 
curve method has been commonly used. Using internal standard (IS) with this method has 
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helped to correct for fluctuations in signal intensity For mass spectrometry applications, 
one type of internal standard can be an isotopically enriched form of the analyte of 
interest. For example, Harwood, et al. used isotopically enriched GSH-NEM and 
isotopically enriched GSSG as internal standards for the quantitative calibration curve 
based analysis of GSH and GSSG in erythrocytes using LC/MS/MS (11). In their 
application, to plot the calibration curves, the x-axis represented the concentration of the 
analyte, while the y-axis represented the natural abundant analyte/internal standard peak 
area ratio. 
 Literature values for the GSH/GSSG ratio in healthy adult subjects range from 
about 10 to 1 (12), to 200 to 1 (13), to 1000 to 1 (11), as shown in Figure 1 below: 
 
 
Figure 1 – Literature values for GSH/GSSG ratio in red blood cells 
 
It should be noted that the method for calculating the GSSG concentration described in 
reference 12 was an indirect one which consisted of subtracting the reduced GSH 
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concentration from the tGSH concentration. According to Michaelsen, et al., indirect 
measurement of GSSG and inadequate prevention of artificial GSSG formation can lead 
to inaccurately high results for the GSSG concentration (13).  
 In our work, an advanced application of isotopically enriched analytes for 
quantitative analysis is, as mentioned in chapter 1,  EPA Method 6800A (14). One of the 
procedures described in this method, IDMS, involves spiking the sample with a known 
amount of enriched analyte, performing mass spectrometry measurements on the 
prepared sample, and calculating the concentration of the analyte based on peak area 
ratios. No traditional calibration curves are used in this method. An application of IDMS 
for tGSH analysis in red blood cells will be described later in this chapter.  A more 
advanced procedure described in EPA Method 6800A, speciated isotope dilution mass 
spectrometry (SIDMS), involves spiking the sample with known amounts of the enriched 
analytes of interest (and pairs of related analytes), analyzing the sample by mass 
spectrometry, and determining concentrations and extent of species interconversion by 
analyzing analyte MS peak ratios. This method can be used for GSH/GSSG analysis, as 
GSH to GSSG conversion can occur during sample preparation (although there are 
techniques for minimizing this conversion, which will be discussed later), and correction 
of the conversion is necessary to assess the analytes accurately.  This application of 
SIDMS for optimizing GSH and GSSG analysis was a major part of my research and this 
PhD project, as was the application of IDMS for optimizing tGSH analysis.  
In a collaborative project with the Kingston research group of Duquesne 
University and the Children’s Institute in Pittsburgh, IDMS was used for the analysis of 
tGSH, and SIDMS for the analysis GSH and GSSG, in red blood cells from autistic 
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children before and after exposure to a therapeutic cleanroom environment (this 
collaborative project will henceforth be referred to as the “cleanroom study”). A second 
collaborative project involving the same kinds of analyses for a set of 30 control and 30 
autistic patients was also undertaken (this second collaborative project will henceforth be 
referred to as the “red blood cell study”). This application of the developed measurement 
methods in these studies is described next. 
 
3A – Analysis of tGSH, GSH and GSSG in Red Blood Cells from Autistic Children 
Exposed to Cleanroom 
 
Materials and Methods 
 Cleanroom Study and Red Blood Cell Study Samples 
Both the cleanroom and red blood cell studies were funded with grants obtained 
by Professor Kingston in collaboration with Dr. Scott Faber (M.D.) of The Children’s 
Institute. Both studies were IRB approved, and the grants for them were registered with 
both institutions. In the cleanroom study, blood samples from ten autistic children were 
taken before and after a two week clean room exposure (12 hours per day). These 
samples were obtained in the child’s home from a registered phlebotomist, Ms. Becky 
Pekar. Following the sample handling procedure described by Michaelsen, et al. for 
minimizing GSH oxidation, the blood was drawn from the vein into tube containing 
anticoagulant (Na2EDTA) and immediately put on ice and protected from light, (13). As 
these were regional studies, all patients were within a one-hour driving distance of 
Duquesne and The Children’s Institute; thus, samples could be transported to Duquesne 
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within 2 hours. All patients were within one hour driving distance of Duquesne and The 
Children’s Institute as these were regional studies.  The samples were aliquoted into tared 
1.7 mL polypropylene microcentrifuge tubes from VWR (Randor, PA, part number 
87003-284) under inert atmosphere (Nitrogen) conditions. For the first 6 cleanroom 
samples, either a nitrogen glove box shared by others in the Chemistry Department at 
Duquesne or a nitrogen glove bag was used; for the rest of the samples, a dedicated 
nitrogen glove box specifically for the Kingston research group was used. The samples 
were then centrifuged using a Sorvall Discovery M150 SE centrifuge with an S120AT2 
rotor (ThermoFisher, Asheville, NC) at 2,000 x g at 4
o
C for 15 minutes to separate the 
plasma from red blood cells. The plasma layer above the red blood cells was removed 
and transferred to microcentrifuge tubes, then the small buffy coat containing the white 
blood cells which remained above the red blood cells was removed and discarded. The 
red blood cell and plasma samples were weighed on an analytical balance, then, placed 
into the   -80
o
C freezer for storage. 
 
Chemicals/Reagents  
Isotopically enriched GSH with two 
13C’s and one 15N and isotopically enriched 
GSSG with four 
13C’s were obtained from Cambridge Isotope Laboratories (Andover, 
MA). With both enriched standards, the enrichment was on the glycine. Natural abundant 
GSH was obtained from Sigma-Aldrich (St. Louis, MO, p/n G4251-10G). Natural 
abundant GSSG was obtained from Sigma (p/n G4501-1G). HPLC grade acetonitrile was 
obtained from Sigma-Aldrich (p/n 27,071-7). ammonium formate and 88% formic acid 
were obtained from Fisher Scientific (Pittsburgh, PA – p/n’s A666-500 and A118P-500, 
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respectively). DTT and NEM were both obtained from Sigma-Aldrich (p/n’s D5545-5G 
and E1271-5G, respectively).  
 
Equipment 
 The column used for both the tGSH analysis and the GSH/GSSG analysis was a 
Waters Atlantis HILIC Silica, 3µm, 2.1 x 100 mm (Waters Corporation, Milford, MA, 
p/n 186002013). The system used for LC/MS/MS analysis was an Agilent 6460 Triple 
Quadrupole Mass Spectrometer with an Agilent 1200 HPLC system and Mass Hunter 
software (Agilent Technologies, Santa Clara, CA). For the analysis of the samples using 
the autosampler, polypropylene 96 well plates with 0.5 mL wells (Agilent p/n 5042-1386) 
and silicone coverings with pre-slit well caps (Thermo Scientific, p/n 276011) were used. 
For the pre-concentration of sample solutions by evaporating off the solvent and 
redissolving in a smaller volume, a SpeedVac (made by what was formerly Savant, now 
Thermo, model number SVC 100D) was used for evaporation purposes. For 
centrifugation of the samples after protein denaturation, the Sorvall Discovery M150 SE 
centrifuge with the S120AT2 rotor (Thermo Scientific) was used. Polypropylene 
microcentrifuge tubes (1.7 mL) were obtained from VWR (Randor, PA, part number 
87003-294). 
 
Sample Preparation for the analysis of tGSH 
 Frozen aliquots of the red blood cells were removed from the -80
o
C freezer and 
thawed.  30.0 mg of sample were added to 1.7 mL polypropylene microcentrifuge tubes 
and treated with 30.0 mg of 2.09 µmol/g isotopically enriched GSH. The concentration of 
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the enriched GSH in the solution that was added to the red blood cells was determined by 
a procedure known as reversed isotope dilution mass spectrometry (RIDMS), which will 
be described in more detail later in this chapter). Also added were 300 mg of a freshly 
made aqueous solution of ~ 10,000 ppm DTT. After 20 minutes, ~ 1 mL of acetonitrile 
was added to denature the proteins, and the samples were centrifuged at 4
o
C at 5,000 x g 
for 10 minutes. The supernatants were removed and used for analysis by LC/MS/MS.  
Sample preparation was done in triplicate, and analysis was done in duplicate for a total 
of six replicate analyses, (n=6). For method validation, an aqueous solution of GSH with 
a known concentration 2.30 µmol/g was analyzed as well.    
 
Sample preparation for analysis of GSH and GSSG  
The red blood cell sample in the 1.7 mL microcentrifuge tube (mass of sample in 
the tube was already known before removal from the freezer, usually ~400 mg) was 
treated with 800 µL of ~ 8,000 ppm NEM in a nitrogen glove box while thawing, and a 
250 mg aliquot of this NEM treated sample was spiked with 40.0 mg of 2.95 µmol/g 
isotopically enriched GSH. The sample was also spiked with 35.0 mg of a solution of 
enriched GSSG that had been diluted 50 fold with H2O just before spiking (original 
concentration of enriched GSSG stock solution – 1.95 µmol/g). The concentrations of 
enriched species were determined by RIDMS, described in more detail later in this 
chapter.  Each sample was allowed to equilibrate for 30 min, after which it was treated 
with HPLC grade acetonitile to denature the proteins, then centrifuged at 5,000 x g for 3 
min at 4 
o
C. The supernatant was removed, the solvent from the resulting supernatant was 
evaporated off using a SpeedVac at medium heat (40 
o
C), and the resulting residue was 
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dissolved in 30 µL of DDI H2O, after which ~ 100 µL of HPLC grade acetonitrile were 
added. This final solution was used for analysis.  Sample preparation was done in 
triplicate, and analyses in duplicate (n=6). For method validation, an aqueous solution 
containing known concentrations of reduced GSH (2.00 µmol/g) and GSSG (0.0601 
µmol/g) was made and analyzed as well. 
 
Preparation of aqueous solutions of the enriched GSH and GSSG 
Both enriched GSH and GSSG are very expensive. 50 mg of the former costs over 
$700, and 50 mg of the latter costs over $2,000. One way to use both in a cost efficient 
manner is to use only a few mg to make aqueous solutions of each of them, aliquot those 
solutions into 1.7 mL polypropylene tubes, and store those tubes with the solutions in the 
-20
o
 C freezer. Studies have shown that aqueous solutions of GSH and GSSG to be used 
for analysis can be stored for months at -20
o
C (5, 15). Because the low mass of enriched 
material used can lead to greater uncertainty in the concentration calculation, one can 
instead analyze the concentrations of the solutions by taking aliquots of them out of the -
20
o
C freezer and determining the concentrations of them using RIDMS, which is 
described in EPA Method 6800a (14).  To use this method for the calibration and 
validation of the enriched GSH, for example, an aqueous solution of known concentration 
of natural abundant GSH (which is relatively inexpensive) was made, and a known 
amount of this solution was used to spike a known amount of the frozen and thawed 
solution of enriched GSH. The spiked solution was then treated with DTT, followed by 
Acetonitrile, just as in the tGSH sample preparation protocol. The solution was then 
analyzed by LC/MS/MS using the same method that was used for the tGSH analysis, 
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described below. Sample preparation was done in triplicate, and analysis in duplicate (n = 
6). The RIDMS calculation is done exactly the same way as the IDMS calculation is with 
the exception that the natural abundant GSH is now considered the enriched form and the 
enriched GSH is now considered the natural abundant form.  Enriched GSSG can be 
analyzed in a similar manner using inexpensive natural abundant GSSG, with the 
exception that no DTT is used, and can be analyzed using the same LC/MS/MS protocol 
as used for the analysis of the GSSG in the red blood cells, described in the next section.  
 
LC/MS/MS Analysis Conditions for the tGSH analysis 
As mentioned earlier, an Agilent (Santa Clara, CA) 6460 Triple Quadrupole Mass 
Spectrometer coupled to an Agilent 1200 Series LC system was used for the analysis. 
The column used was a Waters (Milford, MA) Atlantis HILIC Silica (3µm, 2.1 x 100 
mm), with mobile phase A consisting of 20 mM ammonium formate, pH 3.8, and mobile 
phase B consisting of HPLC grade acetonitrile. The column temperature was 45
o
C, and 
the solvent flow rate was 0.35 mL/minute. The nebulizer gas (nitrogen) temperature was 
300
o
C, and its flow rate was 8 L/minute. The sheath gas (nitrogen) temperature was 
250
o
C, and its flow rate was 11 L/minute. The injection volume was 1 µl, and isocratic 
elution was used. Transitions monitored in positive mode included 308 m/z → 179 m/z 
(for natural abundant GSH) and 311 m/z → 182 m/z (for isotopically enriched GSH). The 
product ion of interest was one resulting from the loss of one pyroglutamate, 129 amu).  
The collision energy was 12V, the capillary voltage was 3500V, the fragmentor voltage 
was 135V, and the dwell time was 50 ms. 
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LC/MS/MS Analysis Conditions for the GSH/GSSG analysis  
 An Agilent (Santa Clara, CA) 6460 Triple Quadrupole Mass Spectrometer 
coupled to an Agilent 1200 Series LC system was used for the analysis. The column used 
was a Waters (Milford, MA) Atlantis HILIC Silica (3µm, 2.1 x 100 mm), with mobile 
phase A consisting of 20 mM ammonium formate, pH 3.8, and mobile phase B consisting 
of HPLC grade acetonitrile. The column temperature was 45
o
C, and the solvent flow rate 
was 0.35 mL/minute. The nebulizer gas (nitrogen) temperature was 300
o
C, and its flow 
rate was 8 L/minute. The sheath gas (nitrogen) temperature was 250
o
C, and its flow rate 
was 11 L/minute. The injection volume was 5 µl, and the gradient used is described in 
table 1 below: 
 
Time % 20 mM 
Ammonium formate 
buffer 
% Acetonitrile 
0 minutes 25 75 
10 minutes 50 50 
16 minutes 50 50 
20 minutes 25 75 
25 minutes 25 75 
Table 1 – Gradient system for HILIC method 
 
Analysis was done in positive mode, and the collision energy used for tandem MS 
purposes for the GSH-NEM complex (which resulted in the primary product ion being 
one with the loss of pyroglutamate) was 12V, and that for GSSG (resulting in the loss of 
two pyroglutamates) was 25V. The transitions monitored included  433 m/z → 304 m/z 
(for natural abundant GSH-NEM), 436 m/z → 307 m/z (for isotopically enriched GSH-
NEM), 613 m/z →355 m/z (for natural abundant GSSG), 616 m/z → 358 m/z (for 
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possible “hybrid” GSSG), 617 m/z → 359 m/z (for isotopically enriched GSSG with four 
13C’s), and 618 m/z → 361 m/z (for possible enriched GSSG completely from enriched 
GSH).  The retention time for the GSH-NEM complex was ~ 3 minutes, and that for the 
GSSG was ~ 8 minutes. The capillary voltage was 3500V, the fragmentor voltage was 
135V, and the dwell time was 50 ms. 
 
Results and Discussion (Note: All results reported at the 95% C.I.) 
Method Validation 
 For the validation of the method for the analysis of tGSH concentration, the 
experimental value obtained, 2.09 ± 0.30 µmol/g, was in agreement with the known value 
of 2.30 µmol/g. For validation of the method for analysis of reduced GSH and GSSG, the 
experimental values obtained, 2.27 ± 0.32 µmol/g and 0.0623 ± 0.0028 µmol/g, 
respectively, were in agreement with the corresponding known values of 2.00 µmol/g and 
0.0601 µmol/g.  
 
Results from cleanroom study 
The tGSH and GSH/GSSG results from the cleanroom study are shown in Figures 2 and 
3, respectively. 
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Figure 2 – Results from tGSH analysis from the cleanroom study 
 
 
Figure 3 – Results from the GSH/GSSG analysis from the cleanroom study 
 
In the clean room study, in the tGSH analysis, no overall change was noticed in 
the before and after tGSH values for the children. Regarding the GSH/GSSG ratio 
analyses, children 6 and 8 are young identical twins girls. The former twin (child 6) had 
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an increase in the GSH/GSSG ratio.  This twin (child 6) showed improvement with 
respect to behavioral characteristics as well (data for behavioral characteristics not 
shown), while the latter (child 8) did not. It was hypothesized that the improvement in 
behavior in child 6 and the absence of such an improvement in child 8 was related to the 
improvement or lack thereof in the GSH/GSSG ratio. An epigenetic relationship was also 
hypothesized, but a conclusive statement regarding such a relationship for the explanation 
of the results from children 6 and 8 is beyond the scope of this discussion. Such a 
relationship between development of autism and possible epigenetic factors has been 
documented in the literature and in the examples documented in “Ghost in Your Genes” a 
documentary relating epigenetics and environmental factors presented by NOVA (16). In 
the NOVA documentary, a case was described involving identical twin sisters of whom 
one twin had autism while the other did not.  Environmental factors and epigenetics were 
considered possible contributing factors by researchers in the documentary, and these 
same factors are related to the study results discussed here.   
Although there was a relatively small sample size (n=10) used in the cleanroom 
study that limited the statistical power and made it difficult to make strong, conclusive 
statements about the results obtained, our research group is, as of this writing, conducting 
a much larger study involving 30 autism patients and 30 healthy controls matched for 
age, gender, and socioeconomic status. This study is described next. 
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3B – Analysis of tGSH in Red Blood Cells from 16 Pairs of Age, Gender, and 
Socioeconomic status matched autistic and control samples 
 
 In an ongoing study which will eventually include 30 young autism patients and  
30 matched healthy controls, blood samples from 16 autism patients and 16 age, gender, 
and socioeconomically matched healthy controls were delivered to Duquesne University 
and processed so as to obtain the red blood samples just like the cleanroom samples were. 
As of this writing, from the perspective of the author, this is still a blind study, as 
information pertaining to which children are the controls and which are autistic is being 
withheld until the end of the study. These 32 samples were prepared for tGSH in a 
manner similar to that used for the analysis of the tGSH in the cleanroom samples. To a 
1.7 mL polypropylene microcentrifuge tube were added 20.0 mg of thawed and 
vigorously shaken (for ~ 3 – 5 seconds) 2.31 µmol/g isotopically enriched GSH, 18.0 mg 
of thawed red blood cell sample, and 160 mg of freshly made ~10,000 ppm DTT. After 
allowing the sample to equilibrate for 30 minutes, 0.6000 g of HPLC grade Acetonitrile 
were added to denature the proteins. The sample was centrifuged at 4
o
C at 5,000 x g for 
10 minutes, and the supernatant was removed and used for analysis. Sample preparation 
was done in triplicate, and analysis of each replicate in duplicate (n=6). The LC/MS/MS 
method used for tGSH analysis was also similar to that used for the cleanroom study 
except that the concentration of pH 3.8 ammonium formate was 10 mM instead of 20 
mM. It had been noticed by our research group that, as the concentration of ammonium 
formate in the solution used as solvent A for the LC/MS/MS method increases, peak in 
the chromatogram becomes more narrow and the signal intensity decreases; conversely, 
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as the concentration of ammonium formate decreases, the peak becomes broader and 
more intense (data not shown). The changing of the ammonium formate concentration 
was intended to optimize the peak width/signal intensity relationship, taking into account 
other parameters, such as the number of SRM transitions. The results of the analysis of 
these 16 pairs of samples are shown in Figure 4 on the next page:
  
6
9 
 
Figure 4 – Results from the tGSH analysis of red blood cells from 16 matched pairs of control and autistic samples  
from the red blood cell study
0
0.5
1
1.5
2
2.5
3
3.5
1B 2B 3B 5B 7B 8B 9B
10
B
11
B
12
B
14
B
15
B
16
B
17
B
18
B
19
B
20
B
21
B
22
B
23
B
28
B
29
B
31
B
32
B
35
B
36
B
37
B
40
B
42
B
43
B
45
B
49
B
tGSH  
(µmol/g) 
tGSH analysis in red blood cells from 16 matched pairs of control and autistic  samples from red blood cell 
study (p = 0.012) 
control and autistic patients 
   70 
 
 The results in Figure 4 were sent to our statistician, Dr. John Kern from Duquesne 
University. He reported that, overall, collectively, the autistic patients had higher red 
blood cell tGSH than the healthy controls (although there was some overlap), and the 
difference was statistically significant (p=0.012). As mentioned in the introduction, a 
study by Adams et al. in which GSH in red blood cells and heavy metals in urine from 
autistic children were analyzed before and after chelation therapy suggested that exposure 
to toxic metals other than mercury, such as lead, aluminum, cadmium, and antimony 
results in higher than normal GSH levels due to the body’s increased GSH synthesis in 
response to exposure to those metals, while exposure to mercury results in lower than 
normal GSH levels, possibly due to the inhibition of GSH synthesis by the mercury (17). 
The study also suggested that, as the body burden of toxic metals is lowered, the 
concentration of GSH in red blood cells normalizes (17). The results obtained thus far in 
our red blood cell study suggest the possibility, but do not yet prove, that the autistic 
patients in our study have, on average, a higher body burden of toxic metals other than 
mercury which resulted in their bodies making more GSH in response to exposure to 
those toxic metals. Further research is needed to confirm this hypothesis. Figure 5 is a 
statistical extension and interpretation of the logistic regression analysis of tGSH in red 
blood cells vs. autistic diagnosis probability for 32 children. The calculations used for 
Figure 5 were performed by the statistician on our research team, Dr. Kern.  
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Figure 5 – Statistical extension and interpretation of the logistic regression analysis of 
tGSH in red blood cells vs. autistic diagnosis probability for 32 children (n= 16 matched 
pairs). 
 
The graph is based on the overall probability of a 1, 2 or 3% chance of having an autistic 
child in a population such as Western Pennsylvania. To explain further, if the overall 
prevalence of autism in western Pennsylvania is, for example, 2% (blue line), the 
probability of a child with a red blood cell tGSH concentration of 1.8 µmol/g having 
autism is extremely low (no more than a random sample from the general population), 
but increases as the tGSH concentration increases such that, at a concentration of 2.6 
µmol/g, for example, the diagnostic probability exceeds 15%.   
Our research group is following up on this work by analyzing the remaining 14 
pairs of control and autistic samples for red blood cell tGSH, as well as all 60 red blood 
cell samples (30 control and 30 autistic) for GSH/GSSG analysis. While the GSH/GSSG 
ratios for these same patients were not available at the time of this chapter presentation, 
tGSH in red blood cells (µmol/g) 
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this data is being accumulated and will, very likely, be presented as a final addendum to 
this chapter.    
In both the cleanroom study and the red blood cell study, although steps were 
taken to minimize the conversion of GSH to GSSG in the blood samples prior to their 
arrival at Duquesne, such as drawing the samples into blood draw tubes via vacuum 
suction without exposing them to atmospheric oxygen, keeping the samples in ice,  and 
protecting them from light during transport, additional work is currently being carried out 
by our research group to improve this methodology so that whole blood samples obtained 
from nonlocal settings can also be analyzed for both tGSH and GSH/GSSG.  In addition, 
research into enabling long distance transport of these blood tubes with correction by 
field and remote automatic spiking is being carried out at the present time.  The progress 
made so far in this area by our research group is described next. 
 
3C –  Enabling sampling of tGSH and GSH/GSSG in blood sample from remote 
locations 
 A recent paper by Rossi, et al, describes using a blood draw tube containing 
Na2EDTA (anticoagulant) and NEM for the purpose of preventing the conversion of GSH 
to GSSG after the blood is drawn into the tube and transported to the nonlocal laboratory 
for analysis (18). Although their experiments included only the analysis of reduced GSH 
(specifically, GSH conjugated with NEM) and did not include GSSG analysis, they did 
demonstrate the potential for obtaining samples from nonlocal settings for reduced GSH 
analysis. Our research group at Duquesne University, in collaboration with Applied 
Isotope Technologies (AIT – Pittsburgh, PA), and the Open Medicine Institute (Mountain 
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View, CA), is continuing the remote measurement work by preparing a blood draw tube 
containing Na2EDTA and a solution containing NEM, isotopically enriched GSH, and 
isotopically enriched GSSG, and using this blood draw tube to obtain and analyze a blood 
sample from a nonlocal setting. The details of this protocol are described next. 
 
Materials and Methods 
 The same reagents used in the cleanroom and red blood cell studies for sampling 
and quantifying of tGSH and GSH/GSSG were used in this study. A solution containing 
~ 4,000 ppm NEM, 0.919 µmol/g enriched GSH, and 0.00317 µmol/g enriched GSSG 
was made and put into a 7 ml capacity blue capped blood draw tube containing 10.5 mg 
of Na2EDTA as an anticoagulant (tube provided by Kendall, which is now part of 
Covidien, Mansfield, MA). This prepared blood draw tube, along with a second and third 
tube containing just the Na2EDTA, were weighed and then shipped frozen to the hospital 
clinical laboratory run by Dr. Andreas Kogelnik MD, PhD, Medical Director.of the Open 
Medicine Institute in Mountain View California. The staff at the Open Medicine Institute 
followed the procedure given to them, which is shown below in a protocol that was 
provided as a standard operating procedure (SOP): 
 
Standard Operating Procedure for Blood Draw Tubes for tGSH and GSH/GSSG 
(begin official SOP document) 
 
Standard Operating Procedure (SOP) for GSH Test Assay 
 
   74 
Blood Draw Tubes for total Glutathione, reduced Glutathione and Glutathione 
Disulfide Test 
AIT-GSH-GSSG-α 
   
PURPOSE To measure the concentrations of total glutathione (tGSH), reduced 
glutathione (rGSH) and glutathione disulfide (GSSG) in whole blood. 
 
  
PRINCIPLE 
 
The values for tGSH and the rGSH/GSSG ratio are often used as 
indicators of the extent of one’s oxidative stress level and have 
applications to autism, chronic fatigue syndrome, cancer, and other 
conditions. 
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APPLICATION Blood samples are drawn into specialized tubes by the phlebotomist, 
 then, following the procedure below are sent to AIT for analysis. 
 
The procedure involves the usage of N-Ethylmaleimide (NEM) 
 already present in the blood draw tube designated for the analysis of 
 the rGSH/GSSG ratio. The purpose of the NEM is to block the thiol  
group on rGSH and, thereby, prevent the conversion of it to GSSG. 
Isotopically enriched rGSH and GSSG, as well as Disodium EDTA,  
are also present in the tube designated for rGSH/GSSG analysis.  
Disodium EDTA is present in the tube for tGSH analysis. 
   
LINKED 
DOCUMENTS 
 
The MSDS’s for NEM, GSH, GSSG, and Disodium EDTA are on file 
 and available upon request. 
 
   
RELATED 
DOCUMENTS 
 
The procedure for preparing the blood draw tube for rGSH/GSSG 
analysis is similar to one described by Rossi, et al. (Analytical 
Biochemistry, 2011, 415, 81-83).  
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SPECIMEN 
REQUIREMENT 
AND 
PREPARATION 
 
 
 
Required specimen is the blood samples that need to be drawn to  
the correct tubes at the specified among, by following the SOP  
detailed in this document. 
  Supplied by AIT: 
MATERIALS 
AND   1. One blood draw tube labeled “throw away,” with code “aaag” 
EQUIPMENT 2. One blood draw tube labeled “tGSH” with code “aaah” 
   3. One blood draw tube labeled “rGSH/GSSG” with code ”aaaj” 
   4. Three pieces of bubble wrap to be used for re-packing the tubes 
  5. Ziploc bags with special packing material, to be used for re- 
  packing tubes 
   6. Federal Express form to be used to ship the tubes back to AIT 
   7. Cold packs 
    
Supplied by the customer: Facility, blood draw equipment (syringe, needle, etc.), -20 
o
C 
freezer, phlebotomist 
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QUALITY 
CONTROL/ 
QUALITY 
ASSURANCE 
 
This SOP is a part of final test development project conducted by 
 AIT which supplies all the material and implement quality 
assurance protocols associated with this project. 
 
   
DEFINITIONS rGSH→ reduced glutathione,  
GSSG → glutathione disulfide, 
tGSH → total glutathione  
NEM→N-Ethylmaleimide,  MSDS → Material Safety Data Sheet 
 
   
 
 
PROCEDURE 
 
 
   
1. Upon taking delivery, inspect the package for visible, substantial damage to the box. 
Call AIT (408-472-2333), if damage is observed. 
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2. Open the box without damaging it so that it can be re-used to return the samples. 
Examine the contents – especially the three blood draw tubes (one with a frozen solution 
inside) – for damage and/or leaks that can be observed by eye. Please see the packing list 
at the end of this document. Call AIT, if tubes are damaged or leak occurred during 
transit. Save all the contents of the box, including the packing material. 
 
3. Put the entire box in a –20oC freezer until ready for use. Alternatively, remove the 
contents – blood draw tubes – in container or a tube rack, and put the container in a      –
20
o
C freezer until ready for use. Make sure the tubes are placed in the container stored 
upright in the freezer. 
 
4. Approximately 20 minutes before the blood is scheduled to be drawn, take the three 
tubes out of the freezer. 
Note: Keep the ice-packs in the freezer, so they will be ready to use when 
samples are re-packed for shipment back to AIT. 
 
5. Place the rGSH/GSSG tube (with the 3 mL of solution) into a Ziploc bag, then place 
the tube in the bag upright into a beaker with ambient temperature water to thaw the 
solution inside the tube. After the solution is thawed, gently invert the tube 3 to 4 times to 
facilitate mixing. 
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6. Draw approximately 3 mL of blood from the antecubital vein into the “throw-away” 
tube and discard the tube. The throw-away tube should be at least half full. This 
approximates to about 3 mL volume.   
 
Note: If blood is to be drawn from the patient in sequence with another draw, the 
throw-away will not be needed as long as the draw for GSH test assay is done 
after another draw using the same needle under use. 
 
7. Using the same blood draw needle in the antecubital vein, draw 6 mL of blood into the 
tGSH tube, then draw approximately 3 mL of blood into the rGSH/GSSG tube containing 
3 mL of solution already in it. 
 
8. Mix the contents of the tubes by gently inverting them several times, over the course of 
5 minutes. 
 
9. Put the tubes back into the -20
o
C freezer for storage for a minimum of 2 hours. 
 
10. Ship the samples back to AIT, overnight, with ice packs, in the same insulated box 
that the tubes came in. Specifically, wrap each of the tubes in the supplied bubble wrap, 
put the wrapped tubes along with absorbent paper towels into the small Ziploc bag, seal 
the small Ziploc bag, put the small Ziploc bag along with two frozen cold packs into the 
large Ziploc bag, seal the large Ziploc bag, put the large Ziploc bag into the styrofoam 
box with the shock absorbent material so that the bag is in the center of the box, put the 
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Styrofoam cap on top of the Styrofoam box, put the Styrofoam box back into the 
cardboard box, and tape up the cardboard box with packing tape. Label the outside of the 
cardboard box with the following return address: Applied Isotope Technologies, 2403 
Sidney Street, Ste-280, Pittsburgh, PA 15203. Also, label the outside of the box “Exempt 
Human Specimens.”   
 
CALCULA-
TIONS 
 
Mass spectrometric sample analyses will be carried out by the AIT 
 staff. 
 
RESULTS/ 
INTERP 
-RETATION 
The data will be obtained and interpreted by the staff at AIT. Final,  
tabulated results will be reviewed and approved by Prof. Skip  
Kingston. 
   
REFERENCES 
 
The GSH test was developed by applying Speciated Isotope Dilution  
Mass Spectrometry (SIDMS), a technology codified in RCRA EPA 
 Method 6800. Additional information may be obtained by contacting  
AIT: 
   Matt Pamuku 
   Ph: 408-472-2333 
   E: matt@sidms.com 
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DOCUMENT CONTROL  
 
Author: Timothy Fahrenholz Reviewed by: Matt Pamuku Approved by: Skip 
Kingston, Ph.D. 
Signed: Signed copy on file Signed: Signed copy on file Signed: Signed copy on file 
Date: August 30, 2011  Date: August 30, 2011  Date: August 
30, 2011 
 
Revision: V-1.02.01 
Part No: TBD 
ADDITIONAL INFORMATION 
AIT reserves the right to correct all technical specifications, descriptions, protocols, 
material, deliveries, prices and correct typos, without notice. 
 
This test is still under beta-level development. The recipient agrees to cooperate with AIT 
to accomplish its testing goals. AIT offers no warranties, implied or expressed, and fit-
for-purpose statements associated with this test. The recipient agrees to cooperate with all 
terms and conditions. 
 
PACKING LIST 
Blood draw tube Acceptable condition? (for the tubes, no 
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cracks, leaks, etc) Circle one. 
1. Tube labeled “Throw 
Away” 
yes/no 
2. Tube labeled “tGSH” yes/no 
3. Tube labeled 
“rGSH/GSSG” 
yes/no 
4. Bubble Wrap yes/no 
5. Ziploc Bags yes/no 
6. FedEx Instructions yes/no 
7. FedEx Shipping Form yes/no 
8. Cold Packs yes/no 
 
(End of official SOP document) 
 
After receiving the three blood draw tubes with the blood in them from the Open 
Medicine Institute, the tubes were inspected, and no noticeable damage was observed. 
The tubes were stored at -20
o
C until sample preparation/analysis.  
 
Sample Preparation and Analysis of tGSH in whole blood sample from Open Medicine 
Institute 
 The sample preparation protocol for the analysis of tGSH in the whole blood 
sample was similar to that used for the analysis of tGSH in red blood cells described 
earlier. The blood sample was removed from the -20
o
C freezer and thawed. To each of 
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three 1.7 mL polypropylene tube were added ~ 60.0 mg of whole blood , ~ 15.0 mg of 
2.18 µmol/g enriched GSH, and 150 mg of 10,000 ppm DTT for triplicate sample 
preparation. After 30 minutes, 600 mg of acetonitrile were added to each tube to denature 
the proteins, and the sample preparation replicates were centrifuged at 5,000 x g at 4
o
C 
for 10 minutes, after which the supernatants were removed and used for LC/MS/MS 
analysis. Sample preparation was done in triplicate, and analysis in duplicate (n=6). 
 For LC/MS/MS analysis, the conditions used were similar to those used the for 
the tGSH analysis in the red blood cell study described earlier in this chapter. 
 
Sample Preparation and Analysis of GSH and GSSG in whole blood sample from Open 
Medicine Institute 
 In a personal communication with Dr. Andrew Alpert (one of the world experts in 
hydrophilic interaction chromatography, or HILIC) from Poly LC, Inc., at the 2011 
Pittcon in Atlanta, to improve the sensitivity for the analysis of GSSG, he suggested that, 
in the sample preparation protocol, after evaporating off the solvent with the SpeedVac, 
instead of initially redissolving the residue in water, one should redissolve it in the 
ammonium formate buffer solution used as solvent A in the LC/MS/MS method to help 
with the ionization (19). In another personal communication with Brian Rappold from 
Labcorp at the 2011 American Society for Mass Spectrometry (ASMS) Conference in 
Denver, Colorado, he suggested the usage of a mixture of ethyl acetate and acetonitrile 
(e.g. 10% ethyl acetate), rather than 100% acetonitrile, as solvent B in the LC/MS/MS 
protocol, which would help in the evaporation of the solvent mixture in the electrospray 
droplet and, thus, help improve sensitivity (20). In a PowerPoint® presentation that he 
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gave at the conference, he described using this method to achieve up to a five-fold 
improvement in sensitivity. During a September 2011 mass spectrometry training course 
at Duquesne University given by Dr. Richard King from Pharmacadence Analytical 
Services, LLC, he suggested that, for improving the sensitivity in a given method, one 
way would be decrease the dwell time in the triple quadrupole mass spectrometer (e.g. 
from 50 ms to 5 ms) and, thus, obtain more points per peak (21). These three suggestions 
were implemented in the protocol for analyzing GSH and GSSG in the whole blood 
sample sent back to Duquesne by the Open Medicine Institute. 
 More specifically, for sample preparation, the GSH/GSSG tube from Dr. 
Kogelnik’s hospital clinical laboratory was thawed, and 200 µL aliquots of the spiked 
blood were added to five 1.7 mL polypropylene microcentrifuge tubes. To each tube were 
added 800 µl of acetonitrile to denature the proteins, and these five tubes were 
centrifuged at 5,000 x g at 4
o
C for 10 minutes. The supernatants were transferred to clean 
1.7 ml polypropylene tubes, and these tubes were put on the SpeedVac for evaporation at 
medium heat (~40
o
C) for 1 hour and 45 minutes. After evaporation, to the first tube with 
the residue were added 40 µL of 20 mM ammonium formate, pH 3.8, which was pipetted 
up and down in the tube ~ 4 times, after which the solution in the first tube was 
transferred to the second tube, where the up and down pipetting technique was repeated, 
and so on, down to the fifth tube, so that the residues from all five tubes were pooled. To 
the tube with the solution of pooled residue were added 60 µL of acetonitrile, and the 
solution was analyzed using conditions similar to those used for the GSH/GSSG analysis 
in red blood cells described earlier in this chapter except that solvent B in the LC/MS/MS 
protocol consisted of 90% acetonitrile and 10% ethyl acetate (Optima brand, Fisher 
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Scientific, p/n E196-4) and the dwell time was lowered from 50 ms to 5 ms.  Four 
analysis replicates were completed (n=4). 
 
Results and Discussion 
 The concentration of tGSH was 1.21 ± 0.7 µmol/g, and that of reduced GSH was 
1.27 ± 0.2 µmol/g. The values for the tGSH and reduced GSH were, thus, statistically 
indistinguishable.  GSSG was detected in two of the four runs, and its calculated 
concentration ranged from 1.60 nmol/g on the high end to ND (not detected). The 
chromatogram from one of these runs is shown in Figure 6. The peaks for the transitions 
of natural abundant GSSG (613 m/z → 355 m/z) and the spiked enriched GSSG (617 m/z 
→ 359 m/z) were weak, as were the peaks for the “hybrid sandwich” (transition – 616 
m/z → 358 m/z) and the “white bread sandwich” (transition – 619 m/z → 361 m/z).  
Although further research is needed to improve the sensitivity for GSSG detection, these 
results represent a step toward the goal of performing direct quantitation of GSSG, as 
well as GSH, in a whole blood sample from a nonlocal setting using SIDMS technology.  
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Figure 6 – GSSG transitions in LC/MS/MS chromatogram from analysis of spiked whole 
blood sample 
 
 Researchers, such as Steghens, et al. have found the concentration of GSSG to be 
significantly lower (7 – fold) in whole blood samples than in red blood cells from healthy 
adults, thereby making the detection of it in the former matrix more difficult than in the 
latter one (22). The Steghens research group analyzed blood samples from 20 healthy 
adults for reduced GSH and GSSG concentration using LC/MS and found the mean 
reduced GSH concentration to be 1.31 ± 0.12 mM and the mean GSSG concentration to 
be 0.64 ± 0.22 µM. They, too, found the analysis of GSSG in whole blood to be difficult, 
613.1 m/z → 355.1 
m/z  
616.1 m/z → 358.1 
m/z - 
617.1 m/z → 359.1 
m/z 
619.1 m/z → 361.1 
m/z 
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as evidenced by the mean S/N ratio reported being between 5 and 6 for the analysis of 
GSSG in the 20 samples. Future work in our research group will involve further 
optimization of our method for analysis of the GSH/GSSG ratio in whole blood for our 
remote blood draw tube project. 
As discussed, GSH forms conjugates with various species of mercury. That being 
the case, the development of methods for the analysis of such conjugates in the body 
would complement the analysis of GSH. An important step toward this end would be the 
initial development of methods for quantitatively (not just qualitatively) analyzing these 
conjugates in simple matrices so that those methods can be further modified for more 
complex matrices, such as blood, plasma, and urine. GSH holding the conjugate toxicants 
is one set of analytes for which quantitative analysis may aid in diagnosis and treatment 
of several conditions.  Since GSH is a first line of defense in the immune system and is a 
major detoxification mechanism in the human body, investigating quantification of 
glutathione with the toxicant was another major scope of assessment in this research. 
Methods for these kinds of analyses in simple aqueous matrices are described in the next 
section. 
 
3D -  Analysis of Conjugates of GSH with Mercury Species 
 Positive mode ESI-MS analysis of a GSH conjugate with Hg
2+
 by Burford, et al. 
showed that, because of the divalent nature of Hg
2+
, two GSH molecules can combine 
with one Hg
2+
 to produce a conjugate in which the most abundant peak appears at 815.1 
m/z (23).  Further research in this area by Feldmann, et al. also demonstrated that both 
Hg
2+
 - GSH and CH3Hg
+
 - GSH conjugates, as well as conjugates of those two mercury 
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species with cysteine, could be detected by ESI-MS, with the characteristic mercury 
isotopic fingerprint being easily observed in all cases (24). This isotopic fingerprint can 
be observed in a GSH conjugate with C2H5Hg
+
 as well. An experiment carried out by our 
research group which demonstrates this idea is described next. 
 
Analysis of GSH Conjugates with three Mercury Species by nano-ESI-TOF-MS 
Materials and Methods 
 An aqueous solution containing 0.0015% GSH (Sigma-Aldrich, St. Louis, MO), 
0.1% formic acid (Sigma-Aldrich) , 50% Optima Acetonitrile (Fisher Scientific, 
Pittsburgh, PA), 10 ppm Hg
2+
, 10 ppm CH3Hg
+
, and 10 ppm C2H5Hg
+
 (Applied Isotope 
Technologies, Pittsburgh, PA) was prepared and analyzed by nano-ESI-TOF-MS. The 
system used for detection was an Agilent 6220 TOF-MS with Chipcube Technology. 
Analysis was carried out by direct infusion (Agilent infusion chip part number G4240-
61002).  The flow rate from the syringe pump (KD Scientific, Holliston, MS, model 
number KDS 100 CE) was 70 µL/hour. The capillary voltage was 1525 V, the fragmentor 
voltage was 225V, and the Nitrogen gas temperature was 325
o
C.  The run time was 1 
minute. 
 
Results and Discussion: 
Information pertaining to the abundances of the isotopes in mercury, as well as a 
visual display of the isotopic fingerprint, are shown in figure 7, which was taken from the 
webelements.com website (25).  
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Figure 7 – Mercury abundances and isotopic fingerprint (25) 
 
The results from the simultaneous analysis of the three glutathione - mercury conjugates 
are shown in Figure 8: 
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Figure 8 – Simultaneous analysis of glutathione conjugated with three mercury species 
using nano-ESI-TOF-MS 
 
The GSH conjugates of all three mercury species were detected by nano-ESI-TOF-MS 
with the characteristic mercury isotopic fingerprints clearly visible, just as with the 
Feldmann study.  
 
Extending GSH and Conjugate Quantification to IDMS and SIDMS by MALDI  
 As helpful as it is to perform qualitative analysis of glutathione conjugates with 
these mercury species, quantitative analysis of these analytes would provide more 
524.0873 m/z 
538.1041 m/z 
CH3Hg
+
-GSH C2H5Hg
+
-GSH 
815.1457 m/z 
Hg
2+
-GSH 
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information regarding the extent of one’s toxic burden of these mercury species, if 
detected in the body. Additionally, the development of a quantitative method for 
analyzing these conjugates using Matrix Assisted Laser Desorption Ionization (MALDI)-
MS, along with nano-ESI-TOF-MS would be useful as well, as both MALDI and ESI are 
soft ionization ionization techniques. An experiment demonstrating the quantitative 
analysis of a Hg
2+
 - GSH conjugate using IDMS is described next. 
 
3E - Quantitative Analysis of Hg
2+
 - GSH Conjugate by nano-ESI-TOF-MS and 
MALDI-TOF-MS using IDMS 
 
 There was a time when quantitation using MALDI-MS did not have wide 
popularity, likely, in part, due to the difficulty of obtaining accurate and precise and 
accurate quantitative results with a significantly fluctuating signal, as well as 
irregularities in the analyte distribution in the spots on the MALDI target. More recently, 
however, quantitation with MALDI-MS has become more prevalent. One factor 
contributing to this shift has been the use of internal standards to correct for signal 
fluctuation (26), which is also an advantage that the use of IDMS has.  Our research 
group has achieved quantitation of GSH conjugated to Hg
2+
 by both nano-ESI-TOF-MS 
and MALDI-TOF-MS using IDMS. This experiment is described next. 
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Materials and Methods   
Quantitative IDMS with nano-ESI-TOF-MS 
  An aliquot of an aqueous 480.3 ppm natural abundant Hg
2+
 standard (~0.2000 g) 
was spiked with ~ 0.2000 g of isotopically enriched 
199
Hg
2+
 (Applied Isotope 
Technologies, Pittsburgh, PA) along with ~ 0.02000 g of ~50,000 ppm GSH, (Sigma-
Aldrich, St. Louis, MO). ~1.6000 g of H2O and ~1.6000 g of Optima methanol (Fisher 
Scientific, Pittsburgh, PA). This preparation of the IDMS sample was done in duplicate, 
as were the IDMS blanks, which were prepared like the IDMS samples were except that 
no natural abundant Hg
2+
 was added. These solutions were each analyzed six times 
(n=12) by nano-ESI-TOF-MS with Agilent chipcube technology using the conditions 
described for the analysis of the three mercury – GSH conjugates earlier in this chapter. 
 
 Quantitative IDMS with MALDI – TOF-MS 
  An aliquot of an aqueous 480.3 ppm natural abundant Hg
2+
 standard  (~0.04800g) 
was spiked with ~0.10000g of isotopically enriched 
199
Hg
2+
,(Applied Isotope 
Technologies, Pittsburgh, PA)  along with ~0.02000g of ~50,000 ppm GSH, ~0.05000g 
of H2O, and ~0.07000g of ~5,000 ppm sinapic acid (Arcos Organics, Geel, Belgium) in 
Optima methanol. This preparation of the IDMS sample was done in duplicate, as were 
the IDMS blanks, which were prepared without natural abundant Hg
2+
. Each of these 
solutions were spotted (2 μL) on a gold MALDI target (Agilent p/n G1972-60025) twelve 
times (n = 24), and the spots were allowed to air dry at room temperature for three hours. 
The target was analyzed using Agilent MALDI-TOF-MS using the following conditions: 
wavelength of laser - 338 nm, Capillary Voltage - 2300 V, Fragmentor Voltage - 150 V, 
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Gas Temperature: 325 
o
C, run time for each spot - 1 minute (the laser was applied to 
several points on the spot over the course of 1 minute, and the average result over the 
course of this 1 minute was obtained). 
 
 Additional steps   
Along with both the nano-ESI and the MALDI runs were analyzed an additional 
solution of natural abundant Hg
2+
 to determine the preliminary mass bias correction. 
When GSH conjugates with Hg
2+, 
 two GSH molecules bind to one Hg
2+
, such that, in 
positive mode ESI and MALDI, the most intense peak appears at ~815 m/z and the fourth 
most intense peak appears at ~812 m/z. These peak intensities approximately (but not 
exactly) quantitatively parallel the most abundant isotope in elemental Hg (the 
202
Hg 
isotope) and the fourth most abundant isotope in elemental Hg (the 
199
Hg isotope), 
respectively, in terms of isotope abundance. The 812/815 ratio was used for the IDMS 
calculation. The preliminary mass bias correction was done with the understanding that 
the initial answer obtained from it represented only an approximation of what the correct 
Hg
2+
 value should be. An additional correction was made by analyzing a known 940.5 
ppm Hg
2+
 solution using the nano-ESI method described earlier, and calculating the 
answer by an IDMS algorithm developed in our laboratory. The actual known value 
(940.5 ppm) was divided by the experimental value (1350 ppm) to obtain a supplemental 
correction factor of 0.697. This supplemental correction factor was multiplied by the 
initial experimental values from the nano-ESI and the MALDI analysis of the 480.3 ppm 
Hg
2+
 solution to obtain the final experimental value. 
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Results and Discussion  
 The results from the quantitative analysis of Hg
2+
  in GSH conjugate are shown in 
Table 2 
Method Concentration of Hg
2+
 in ppm in GSH 
conjugate (reported to 95% C.I.) 
nano-ESI-TOF-MS with IDMS 485 ± 18 
MALDI-TOF-MS with IDMS 474 ± 73 
Actual value 480.3 
Table 2 – Comparison results from analysis of Hg2+ in glutathione conjugate  
conducted by IDMS-nano-ESI-TOF-MS and by IDMS MALDI-TOF-MS as compared to 
the actual value. 
 
The results for the concentration of Hg
2+
 from analysis of the Hg
2+
 - GSH conjugate in 
the MALDI IDMS studies and the nano-ESI IDMS studies were in agreement with the 
correct value within the 95% C.I. The precision achieved from both methods was better 
than ± 20%. These results demonstrate the potential of performing quantitative analysis 
of mercury-GSH conjugates using IDMS with both MALDI-MS and nano-ESI-MS. 
 
3F - Conclusion  
 This chapter has described several applications involving of EPA Method 6800A 
for the quantitation of analytes which are important to GSH metabolism. Of particular 
importance was the finding, discovered by using EPA Method 6800A, that in the red 
blood cell study, the autistic patients had higher red blood cell tGSH concentrations than 
the healthy control patients did (p = 0.012), suggesting the possibility that the autistic 
patients are making more GSH in response to possible elevated body burden of toxic 
heavy metals, such as lead, antimony, aluminum, and cadmium. Results also showed that 
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EPA Method 6800A could be used to quantitatively analyze a toxic heavy metal species 
(Hg
2+
) with GSH in aqueous laboratory – prepared samples, indicating the potential for 
performing such an analysis in a more complex matrix, such as blood or plasma.  EPA 
Method 6800A can be applied to monitor other analytes of metabolic importance as well, 
such as substrates for enzymes for the purpose of assessing enzyme activity. An 
experiment in which this different type of application was executed is described in the 
next chapter.   
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Chapter 4 - IDMS Analysis of GLA Activity in Tissue Lysates from Mice 
 
Fabry’s disease, also called alpha-galactosidase-A (GLA) deficiency, is caused by 
a lack of or faulty enzyme needed to metabolize lipids.  It is one of a group of 44 
lysasomal storage diseases (LSDs) characterized by the lack of or deficiency of enzyme 
production. GLA deficiency results in the accumulation of glycosphingolipids with 
terminal alpha- galactosyl residues, mainly globotriaosylceramide (Gb3) (1). Symptoms 
include chronic pain, kidney impairment, and cardiac lipid build up (1).  One in 117,000 
people have this particular LSD disease (2). The GLA mechanism is shown below in 
Figure 1(3): 
 
Figure 1 – Human GLA Mechanism, taken from reference 3 
 
In the above mechanism, Aspartate–170 functions as a nucleophile, and Aspartate-231 
functions as an acid in the first step, then as a base in the second step.  
Treatment options for Fabry’s disease include enzyme replacement therapy and 
pain medication (4). Gene therapy for Fabry’s disease represents a potential alternative 
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that can be less expensive over the long term than other treatments. An initial attempt to 
develop a GLA gene therapy animal model was made using fluorescence equipment at 
Allegheny Singer Research Institute with limited success due to the background 
fluorescence from the tissue lysates (5). A collaboration between the Kingston Research 
Group and the Allegheny Hospital (AH) was formed in 2009 and mass spectrometry was 
introduced to take the place of the fluorescence measurements that were less sensitive 
and accurate.  The same samples used for the fluorescence experiments were reanalyzed 
in our Center of Excellence by mass spectrometry and by our research group using IDMS 
with nano-ESI-TOF-MS-MS, and the sensitivity and clarity of the results improved 
significantly over the fluorescence data previously obtained by the Allegheny research 
collaborators. These quantitative methods developed to analytically improve the 
quantitative assessment of a mouse model and new salivary gland gene therapy 
alternative may eventually advance the research into treatment of humans. The 
development and application of these MS measurements is described next and lead to an 
important contribution in medical research published in Human Gene Therapy (6).   
 
Materials and Methods: 
 
Initial work at Allegheny Singer Institute 
Details about the mice that were used in the study, how the gene therapy was 
administered, and how the tissues from the mice were processed are described in detail in 
the referenced literature paper that was published in 2011 in Human Gene Therapy (6). 
Briefly, control and knock out mice were obtained from Jackson Labs and brought to 
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Allegheny Singer Institute. The mice were divided into four categories: 1. wild type – 
normal mice (N = 8), 2. GLA gene deficient – lacked GLA gene (N = 14), 3. GLA gene 
deficient, exposed to low dose of adenovirus particles (1 x 10
9
 particles) with the GLA 
gene (N = 8), and 4. GLA gene deficient, exposed to high dose of adenovirus particles (2 
x 10
10
 particles) with the GLA gene (N = 14). Four days after initial exposure of the 
treatment mice to the adenovirus particles, the mice were sacrificed, and their liver, 
kidney, and brain tissues were harvested, after which these tissues were homogenized and 
subjected to a GLA activity assay using fluorescence.  Differences between gene 
deficient and wild type samples were noticeable, but limited due to the background 
fluorescence from tissue lysates. Because of this limitation, the initial manuscript of the 
paper describing this project was rejected for publication. Over 100 mouse tissue samples 
obtained by AH researchers were reanalyzed by IDMS in the Mass Spectroscopy Center 
of Excellence and the paper was then rewritten around these higher quality analytical 
measurements and resubmitted.  New significance was emphasized and several land mark 
findings were discovered that were new contributions to the research. 
 
Quantitative Mass Spectrometry Development and Analysis at Duquesne University 
In an attempt to increase the clarity of the GLA activity in the control and treated 
mice analysis in the mouse tissue samples by IDMS eliminated the background 
fluorescence problems experienced by the AG collaborators. Over 100 tissue samples 
were reprocessed with the IDMS method, after the GLA assay was completed, subjected 
to an SPE protocol, then analyzed by nano-ESI-Quadrupole time-of-flight Q(TOF)-MS-
MS.  
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Details about the GLA assay and sample preparation for nano-ESI-QTOF-MS-
MS analysis are mentioned in the paper describing this research project, which was 
published in Human Gene Therapy earlier this year with greater clarity of result 
significance over the previous fluorescence data previously submitted and rejected for 
publication (6). Briefly, the IDMS method was a modification of a procedure from Gelb 
et al. (7) originally designed for blood spot GLA analysis. An outline for this procedure is 
depicted in Figure 1 below: 
 
Figure 1 – GLA assay described by Gelb, et al. (7) 
 
In the procedure displayed in Figure 1, the sample is spiked with both natural 
abundant synthetic substrate (referred to as “Fabry Substrate” in the figure) and 
isotopically enriched synthetic standard (referred to as “Fabry Internal Standard” in the 
figure).  If the GLA enzyme is working properly, the ratio of the natural abundant 
product (referred to as “Fabry Product” in the figure) to the isotopically enriched standard 
should be higher than it would be if the enzyme were either absent or deficient. When 
performing ESI-MS-MS on the natural abundant product and isotopically enriched 
standard, the tertiary butoxycarbonyl (t-BOC) group can be fragmented off in the 
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collision cell, resulting in the formation of the natural abundant product ion (384 m/z) 
and the isotopically enriched product ion (389 m/z).  
In the collaborative project between Allegheny Research Institute and our 
research group, for the GLA assay, 15 µL of the assay solution (3.33 mmol/L of GLA-S 
(Fabry substrate in figure 1), 6.67 µmol/L of GLA-IS (Fabry Internal Standard in figure 
1), 160 mmol /L ,N- Acetylgalactosamine, and 0.142 mol/L sodium acetate, pH 4.6) and 
10 µL of tissue homogenate were added to a 1.7 mL centrifuge tube, centrifuged at 1350 
x g for 1 minute, and then incubated at 37
o
C for 20 minutes. After incubation, the tube 
was briefly centrifuged, then the reaction was quenched by adding 100 µL of ethyl 
acetate/methanol 1:1. 400 µL of ethyl acetate, followed by 400 µL of H2O were added 
and mixed with up and down aspiration in the pipette tip. The tube was then centrifuged 
at 1350 x g for 5 minutes to get the two phase separation.  300 µL of the top organic layer 
was transferred to a clean 1.7 mL microcentrifuge tube.  
 
Additional Sample Cleanup 
Further sample preparation was carried out by our research group at Duquesne to 
optimize detection of the analytes by nano-ESI-TOF-MS-MS.  This protocol involved 
SPE using hydrophilic interaction liquid chromatography (HILIC).  The SPE column 
used was a UCT (Bristol, PA) diol column, with 200 mg of sorbent and a 1 mL volume. 
The steps used in the SPE procedure are described next: 
 
Step 1 - Condition SPE column with 1.8 mL of acetonitrile/H2O 80/20 
Step 2 - Add 150 µL from the 300 µL ethyl acetate solution to the column 
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Step 3 - Run 1 mL of acetonitrile/H2O through the column and collect eluent 
Step 4 - Add 2 µL of 90% formic acid to the eluent to help with ionization 
 
nano-ESI-QTOF-MS-MS conditions  
The conditions used for the analysis were as follows: system – Agilent chipcube 
with infusion chip (Agilent part number  G4240-61002) and 6530 QTOF, syringe pump 
flow rate – 70 µL/hr, capillary voltage – 1450V, fragmentor voltage – 150V, collision 
cell – 20V, gas temperature – 325oC, drying gas flow – 4L/min, run time – 1 minute. 
Analytical runs were completed in triplicate.  
 
Results and Discussion: 
An example MS/MS spectrum from a gene deficient sample is shown below in Figure 2: 
 
• Figure 2 - The peak at ~384.2279 m/z is the product ion from the natural abundant   
enzyme-substrate reaction product (theoretical m/z = 384.2282); the one at ~ 
389.2584 m/z is the product ion from the isotopically enriched form of the analyte  
(theoretical m/z = 389.2595)  
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An example MS/MS spectrum from a wild type sample is shown below in Figure 3: 
 
• Figure 3 - The peak at ~384.2283 m/z is the product ion from the natural abundant   
enzyme-substrate reaction product (theoretical m/z = 384.2282); the one at ~ 
389.2584 m/z is the product ion from the isotopically enriched form of the analyte  
(theoretical m/z = 389.2595)  
Figure 4 on the next page shows the comparison between the results from the fluorescent 
assay and those from the isotope dilution - MS/MS analysis:
    
1
0
7 
 
 
Figure 4 – Results from both the fluorescent assay and the MS/MS assay. 
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The florescence spectroscopy assay does not have the fidelity to distinguish between the 
low dose mice, and a lack of quantitative fidelity diminished the significance of the tissue 
samples.  In direct comparison, the IDMS data was able to show the differences in the 
animal model. 
The clarity of the results using the isotope dilution – MS/MS analytical method  
demonstrated that the fluorescence method lacked the fidelity and quantitative accuracy 
to dramatically emphasize the significance of the animal model. As a result of these 
improved analytical results being obtained, the paper for this project was resubmitted for 
publication with the MS/MS results, and the publication was accepted (6). 
For future work, research is ongoing to develop a gene therapy method without 
having to use a viral delivery system. The method involves sonication through the 
animal’s salivary gland and will be evaluated using the MS/MS method described in this 
chapter.  
 
Conclusion 
This chapter described experiments involving the application of IDMS TOF-MS 
for quantitative analysis of enzyme activity. Results showed that this method provided 
superior methodology for enzyme activity analysis compared to more conventional 
methods, such as the fluorescence spectroscopy assay mentioned earlier.       
The use of TOF-MS, being a high resolution method, with mass accuracy usually 
within ± 5 ppm, can also be used to confirm results for the identification of compounds 
obtained from other analytical methods, such as 
1
HNMR. GC/MS, which uses electron 
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ionization at 70 eV and yields mass spectrometry data with virtually compound-unique 
fragmentation patterns, can also be used to complement 
1
HNMR results. This application 
of TOF-MS and GC/MS is described in the next chapter. 
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Chapter 5 – Mass Spectrometry Service Analysis 
 
 For organic and medicinal chemists to get their research published, they need to 
demonstrate that the synthetic schemes for their compounds of interest are successful by 
confirming the identity of the final products in those synthetic schemes by using at least 
two independent analytical methods.  If one wants to publish in the Journal of Organic 
Chemistry (JOC), for example, one needs to provide both 
1
HNMR and 
13
CNMR results, 
along with results from either HRMS analysis or elemental analysis (1). For HRMS 
analysis of compounds below 1,000 G/mol, this journal considers results within 0.003 
m/z of the theoretical value to be considered acceptable. This journal also allows for 
theoretical values to include ones in which atoms are added to the analytes’ ions,, such as 
when sodium adducts are formed. 
 At Duquesne University (DU), first a walk up use of the Agilent TOF was 
attempted for groups wishing to use the mass spectrometer to do their own HRMS data 
for their publications. This experiment proved to be unsuccessful as the students did not 
take the care to prepare the sample properly, filter them, or dilute them, and the 
instrument frequently had to be repaired as a result. This practice was abandoned. It was 
then reformulated to have these graduate students from these synthetic laboratories 
submit their samples to an experienced analytical chemist who, initially, was Dr. 
Stephanie Wetzel from the Chemistry and Biochemistry Department at Duquesne 
University and, later on, after receiving training from Dr. Wetzel, was the author of this 
dissertation. The analyst would manage the final preparation and the instrument oversight 
and analyses. This proved to be successful for over three years, and an experiment was 
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commenced to see how the support of other laboratories would proceed under these 
conditions and what would be the use and need and talent needed to successfully create 
an HRMS service laboratory system.  This was done for free as an experiment in the 
Department of Chemistry and Biochemistry on the NSF MRI granted instrumentation 
that had been received and completed in its construction in 2006 through 2011.   
For these years, the Kingston Research Group has been supporting the chemistry 
faculty and the pharmacy faculty by providing these services using the NSF granted 
instrument. The author of this dissertation has been the analyst in recent years performing 
these analyses and has been on a Research Assistant (RA) funded in the Professor 
Kingston performing these analyses as an experiment of service to the DU synthetic 
chemists.  These in-house HRMS analyses have been a free service for research groups in 
both the Chemistry and Pharmacy departments and the use of the facility has grown to 
over 200 HRMS samples per year. The monetary value of this service can be seen as 
considerable given the fact that other universities, such as the University of Iowa, charge 
their within-university staff for HRMS analysis. The rate at the University of Iowa for 
HRMS analysis, for example, is $59 per sample (2). At Duquesne University, just in 2010 
alone, approximately 200 HRMS samples were analyzed for no charge for research 
groups in the Chemistry and Pharmacy departments. Had the pricing system of the 
University of Iowa been in place at Duquesne, the HRMS samples analyzed in 2010 for 
the Duquesne research groups would have cost over $11,000. This represents a 
significant savings for the university. 
 When samples are submitted to the analyst at Duquesne for HRMS analysis, the 
samples come with a submission form which gives the analytical chemist information as 
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to what analyte m/z values to look for. Included in this submission form is also a section 
where the proposed structure of the compound is to be given. This helps the analyst 
because it provides information regarding what functional groups are present and how 
polar the compound is, which, in turn, enables the analytical chemist to decide how to 
best analyze the sample. This chapter has been prepared to both document the 
development of this capability and to permit this service should this service be continued.  
 A description of the structure the organic molecule including polarity is essential 
for the analytst to determine how best to analyst the sample.  For example, polar 
compounds with amines are good candidates for positive mode ESI-MS analysis, whereas 
compounds of relatively low molecular weight (~1,000 Dalton or below) and moderately 
low to intermediate polarity would be good candidates for Atmospheric Pressure 
Chemical Ionization (APCI)-MS analysis (3). According to Dr. John Greaves, who runs 
the HRMS laboratory at the University of California at Irvine, there are some compounds 
that are so nonpolar that even APCI-MS will not work (4). An example of a case study 
involving the successful analysis of such a compound by the analyst at Duquesne will be 
discussed later in this chapter. 
 Most (about 90%) of the compounds submitted thus far  to the analyst at 
Duquesne can be analyzed using positive mode nano-ESI-TOF-MS by direct infusion 
using the Agilent equipment described in chapters 3 and 4.Typically, the compounds are 
dissolved in either Acetonitrile or Methanol (high purity brand, such as Optima from 
Fisher Scientific, Pittsburgh, PA), and, often, the sodium adduct is the most abundant ion 
detected due to the presence of sodium in the glassware used by the synthetic chemists. 
Although a reasonable analyte concentration for the HRMS analysis would be about 10 
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ppm, usually, when compounds are submitted, no information whatsoever is given to the 
analyst as to what the concentration is. This renders it necessary for the analytical 
chemist, as a precautionary measure, to dilute the sample at least 100-fold to minimize 
the likelihood of overloading the instrument with sample. If it turns out that the 
concentration of the diluted sample is too low, all one has to do is use a higher 
concentration, and only a few minutes are lost. If, however, this precautionary measure is 
not followed, one runs the risk of overloading the instrument with a solution with a 
concentration that is too high (usually over 100 ppm), after which can take several hours 
to flush the compound out of the system. 
 If the analyte is not detected during the HRMS analysis, there can be several 
possible reasons. Some of these possibilities are given below: 
- The concentration was too low. 
- The container and/or HRMS form was mislabeled. 
- The solvent that the compound was dissolved in reacted with the compound. 
- The proper NMR analysis was not completed before sample submission. 
- The compound decomposed while waiting to be analyzed. 
- The appropriate source was not used (e.g. ESI vs. APCI) 
- The appropriate mode was not used (positive vs. negative) 
If the analyte is not detected by the analyst, the analytical chemist who performed the 
HRMS analysis can communicate with the synthetic chemist who submitted the sample 
to determine what, if any, alternative methods can be used. The following three case 
studies represent real examples of situations in which the initial HRMS analysis of the 
submitted samples with the usual positive mode nano-ESI-TOF-MS was not successful, 
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but eventually the desired results were obtained by the analytical chemist. No chemical 
structures will be shown due to the proprietary nature of the compounds that were 
submitted, but general descriptions of the compounds will be given. 
 
Case # 1 
 A sample was submitted by a person from Dr. Fleming’s research group. The 
compound seemed to be present based upon NMR analysis, but the person who submitted 
the sample also mentioned that it was sensitive to oxidation. According to the proposed 
structure that was given to the analytical chemist, the sample was a low molecular weight 
(below 500 amu) compound with a sulfur atom. When the sample was initially analyzed 
using positive mode nano-ESI-TOF-MS, the analyte of interest was not detected. Upon 
further examination however, it was noticed that there were three peaks detected which 
were about 16 m/z units higher than their corresponding expected [M+H]
+
, [M+Na]
+
, and 
[M+K]
+
 peaks. When the proposed structure was modified to include an additional 
oxygen atom, the experimental m/z values were in agreement with the theoretical m/z 
values to within 10 ppm error of the theoretical mass. The successful detection of the 
modified compound enabled the person from Dr. Fleming’s group who submitted the 
compound to publish his work in the literature. 
 
Case # 2 
 A sample was submitted by a person from Dr. Basu’s research group which was 
of moderately low polarity. An initial attempt to analyze the sample by positive mode  
nano-ESI-TOF-MS was not successful. It was hypothesized that the polarity of the 
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sample was too low for ESI-MS analysis. Positive mode APCI-TOF-MS was used 
instead. As a result, the moderately nonpolar compound was successfully detected. 
 
Case # 3 
 A compound with a long hydrocarbon chain, an oxygen atom, and several fluorine 
atoms was submitted to the analytical chemistry staff by a person from Dr. Janjic’s group 
from the Pharmacy Department. The compound seemed to be present according to the 
NMR results, but attempts to analyze the sample by both positive and negative mode 
nano-ESI-TOF-MS were not successful (according to Dr. Schilling from the University 
of Illinois at Chicago, negative mode can be used with the Agilent Chipcube system 
provided that the capillary voltage remains at or below 1600V (5)). Dr. Janjic sent the 
sample to outside laboratories for analysis, and the sample was still not detected by any 
of the commercial laboratories.  At the 2010 ASMS meeting in Salt Lake City, Dr. John 
Greaves, who runs the HRMS laboratory at the University of California at Irvine, after 
being given a general description of the compound without revealing the structure, 
surmised that the compound was so nonpolar that even APCI-MS would not ionize the 
compound. He mentioned that his laboratory had a high resolution GC/MS system and 
that the sample could be sent to him for analysis, but he suggested that the analyst at 
Duquesne analyze it first on low mass resolution GC/MS at Duquesne. After successfully 
detecting it with the low resolution GC/MS at Duquesne, the sample could be sent to him 
for high mass resolution GC/MS analysis. This analysis was carried out by Becky 
Wagner, one of the analytical chemistry graduate students at Duquesne. The following 
conditions were used for the analysis: 
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 System – Agilent 6890N GC coupled with Agilent 5973 MS 
 Sample dissolved in 2-propanol (concentration – 60 ppm)  
 Molecular weight: 432 g/mol 
 1 µL injection volume 
 Injector: 250oC 
 Start oven → 75oC, hold 1 minute 
 10oC/min up to 275oC, hold for 4 minutes 
 Column → HP-5 MS 
 Transfer line temperature: 280oC 
 4 minute solvent delay 
 Range: 40 m/z – 500 m/z  
 
The GC chromatogram is shown in Figure 1 below. The analyte peak of interest was 
detected at ~ 10.5 minutes: 
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Figure 1 – GC chromatogram of sample submitted by Dr. Janjic’s group 
 
The MS fragmentation pattern from the peak at ~ 10.5 minutes in the chromatogram 
(from 240 m/z upward) is shown in Figure 2 below: 
 
Figure 2 – MS fragmentation pattern from 240 m/z upward from peak detected at ~ 10.5 
minutes in the GC chromatogram. 
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In the fragmentation pattern in Figure 2, the parent ion was successfully detected 
at 432 m/z. The peak at 403 m/z represents the loss of an ethyl group (C2H5 → 29 m/z). 
There are several other peaks about 14 m/z units apart, representing the loss of successive 
methylene  groups (CH2), which is common in the GC/MS analysis of compounds with 
long-chain hydrocarbon groups. The continuation of this fragmentation pattern with the 
loss of CH2 groups can be seen from 40 m/z to 240 m/z shown in Figure 3, which is 
shown below: 
 
Figure 3 - MS fragmentation pattern from 40 m/z – 240 m/z from peak detected at ~ 10.5 
minutes in the GC chromatogram 
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The results from the GC/MS analysis were consistent with what was expected for the 
compound submitted by the person from Dr. Janjic’s group. 
 In order for successful HRMS analysis to occur, proper communication between 
the person submitting the sample and the person analyzing the sample must exist.  The 
tools available to the analytical chemist at Duquesne are many, but no one instrumental 
method consisting of a single ionization source is sufficiently robust to detect every type 
of analyte submitted, as the case studies in this chapter demonstrate. Skill and experience 
several ionization systems are necessary for the analyst.  Success comes as a result of 
teamwork, and it is a requirement for the analytical chemist performing the HRMS 
analysis and the organic/medicinal chemist submitting the samples for HRMS analysis to 
exchange necessary information with each other for the program to work properly. The 
analyst can not do the job if the synthetic/medicinal chemist does not provide the 
necessary information, such as what solvent the sample is dissolved in, whether or not the 
compound of interest has been successfully analyzed by 
1
HNMR and/or 
13
C NMR, and 
how to best store the sample until analysis. To assist with this submission process, an 
updated submission form has been developed that has areas where the synthetic chemist 
can submit the necessary information. It was found that safety information was especially 
necessary, and appropriate other information and instructions were necessary as well . 
This form was developed as a result of this several years of experiment and iteration, and 
is attached as an appendix to the dissertation after this chapter.    
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Appendix – Updated draft of Official HRMS submission form 
(Begin form) 
Updated Official Submission Form for HRMS Analysis 
 
Faculty member’s name (printed) _____________________________ 
Faculty member’s signature __________________________ 
Student’s name (printed) _______________________________ 
Student’s signature _______________________________ 
Compound name _________________________ 
Date submitted __________________________ 
Molecular weight _______________________ 
[M + H]
+
 theoretical m/z value __________________ 
[M +Na]
+
 theoretical m/z value __________________ 
[M + K]
+
 theoretical m/z value ___________________ 
Solvent that the sample is dissolved in if submitted in solution form (use either 
acetonitrile or methanol) _________________ 
Concentration of sample in units of parts per million (ppm) ___________________ 
Molecular formula of compound _________________________ 
Safety precautions that need to be taken with the sample: 
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Structure of compound (draw below): 
 
Questions about sample (response for each must be “yes” before submission for HRMS 
analysis) 
1. Has the sample been successfully identified by 
1
H NMR (and, if necessary, 
13
C NMR) 
? (yes/no) 
2. Has the sample been purified to the point where ONLY the analyte peaks show up in 
the NMR (in other words, no peaks from, for example, excess starting material) (yes/no) 
3. Is HRMS analysis necessary as the final step before publication? (yes/no)  
 
General comments: 
Samples submitted merely to  monitor the progress of reactions will not be 
accepted unless, in extraordinarily rare cases,  all other means to do so, such as normal 
phase thin layer chromatography, reversed phase thin layer chromatography, NMR, 
GC/MS, or other methods, have been exhausted. Providing the structure will help the 
person performing the HRMS analysis to determine how best to analyze the sample and 
will, thus, speed up the process. Generally, for compounds of relatively high polarity to 
intermediate polarity, nano-ESI-TOF-MS will be used. For samples that are of 
intermediate polarity or are relatively nonpolar, APCI-TOF-MS will be used. 
(End of form) 
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Chapter 6 – Conclusion 
 
 This dissertation has described research projects involving applications of EPA 
6800A to new areas, such as toxicology, biomarker discovery, and enzyme activity 
analysis. In closing, taking a step back and looking at the big picture, one can see how 
these three applications fit together. The speciation of toxic heavy metals, such as 
mercury, in biological matrices, such as blood, is related to the analysis of possible 
autism biomarker, such as GSH, in those same biological matrices, as the concentration 
of GSH in red blood cells appears to be affected by the body burden of toxic heavy 
metals (1). Toxic heavy metals can also have an impact on enzyme activity via inhibition, 
and it may be that some of the enzymes being inhibited are ones which contribute to GSH 
synthesis, as it has been suggested that GSH synthesis can be inhibited by mercury; 
conversely, toxic metals other than mercury may stimulate GSH synthesis (1).  
 The process of answering one question leads to the formation of more questions 
such that, no matter how many questions one answers, there will always be further 
questions left unanswered. This dissertation is no exception to that rule. One question that 
needs to be answered pertains to why the autistic patients in our red blood cell study have 
higher red blood cell tGSH values than their corresponding controls. It could be that their 
bodies are making more GSH in response to a greater body burden of toxic heavy metals 
other than mercury, but further research is needed to determine this, and EPA Method 
6800A can be used to address this issue by using it for the analysis of heavy metals in the 
red blood cell patients. This work is currently being carried out by my colleague, Greg 
Zinn, a graduate student at Duquesne University. Another question that needs to be 
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addressed more thoroughly pertains to what the metabolic fate of Thimerosal in the body 
is. C2H5Hg
+
, a component of Thimerosal, can interconvert with other mercury species 
during sample preparation and, as was presented in this dissertation, EPA Method 6800A 
can be used to correct for these interconversions; hence, EPA Method 6800A would be 
the ideal method of choice to address this question as well. An additional question that 
needs to be addressed concerns which toxic heavy metals are being bound to which 
biomolecules and in what amounts. The work described in this dissertation pertaining to 
the analysis (qualitative and quantitative) of GSH conjugates with mercury species in 
aqueous solutions provides a starting point, but further work is needed in this area. 
Ideally, one would like to detect the heavy metal bound to the biomolecule by mass 
spectrometry using a soft ionization method, such as ESI or MALDI, and it would be best 
for one to obtain quantitative, rather than just qualitative results. EPA Method 6800A can 
also be used for this area of research. 
 In closing, it is essential for scientists to be open to new ideas. Over the centuries, 
many scientific ideas that were initially met with rejection were eventually accepted. One 
such example occurred with an astrophysicist by the name of Subrahmanyan 
Chandrasekhar. In the 1930s, as a young scientist, he proposed that, if a collapsing star 
has a mass above a certain limit (known today as the Chandrasekhar limit), the star would 
collapse down to what is today known as a black hole. His supervisor at the time, Sir 
Arthur Eddington, strongly rejected this idea, as did Albert Einstein; nevertheless, 
Chandrasekhar’s idea was eventually shown to be correct, and his work in this area 
contributed to his winning the Nobel Prize in 1983 (2). Another example occurred with a 
rocket scientist by the name of Dr. Robert Goddard. In 1920, he proposed that it would 
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one day be possible to send a rocket to the moon. This idea was met with rejection by 
many in the scientific community, as well the popular culture. The New York Times 
newspaper ridiculed this idea. In 1969, 49 years later, a day after Apollo 11 left for the 
moon, the New York Times retracted its statement (3). An additional example occurred 
with my research advisor at Duquesne, Dr. H.M. “Skip” Kingston, when he proposed that 
it would be possible to perform chemistry experiments (extraction, digestion, synthesis, 
etc.) in the microwave which would prove to be more efficient than the more classical 
methods. This idea was initially met with rejection. Some of his colleagues jokingly 
referred to him as “Betty Crocker.” (4). Despite this, the microwave chemistry concept 
eventually gained acceptance in the scientific community, with many publications 
describing the successful use of this methodology being made, including this one.  
In short, a good scientist has the humility to recognize that, no matter how much 
one learns, there is always more to learn. No matter how much one grows, there is always 
room for further growth. 
 St. Albert the Great, patron saint of scientists, pray for us.          
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